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ABRSTRACT

Heparin, a highly sulfated glycosaminoglycan (GAG), is used extensively as an
anticoagulant. It consists of repeating disaccharide units, containing iduronic acid (or
glucuronic acid) and glucosamine, exhibiting variable degrees of sulfation. Heparin, and
its analogues, are used during surgery and dialysis, and are often used to coat indwelling
catheters and other devices where the vascular system is exposed. Administered
parenterally, often continuously due to its short half-life, over 0.5 billion doses are
required per year. Heparin is currently obtained from mucosal tissue of meat animals,
mainly porcine intestine, and to a lesser extent bovine and ovine sources. The early stages
of production are poorly controlled, due to the source of the material. This problem came
into sharp focus in 2008 when the presence of contaminating over-sulfated chondroitin
sulfate in heparin sourced from China resulted in almost 100 deaths in the USA. Coupled
with the fact that only a few doses are obtained from each animal and due to cultural and
religious reasons in some countries, alternative and well controlled sources of heparins
are needed. The FDA and other regulatory agencies are currently considering the
introduction of bovine and ovine unfractionated heparins. Worldwide, there are 1.4
billion cattle, 1.9 billion sheep and goats and 980 million pigs. Both cow and sheep
provide potential alternate sources of porcine heparin. Nowadays, with the advances in
technology and manufacturing processes, higher quality bovine and ovine heparins are

xx

now available in various part of the world and have been shown to exhibit similar
biologic and clinical profiles compared to porcine one.
In this dissertation, we focused on determining the extent of biosimilarity
between BMH, OMH and PMH. And how differences in molecular weight and strcturual
composition may affect the pharmacological activity of these agents. Ten batches of each
heparin were used throughout this project. These studies have shown that BMH, OMH
and PMH exhibit comparable molecular profiles. However, BMH showed weaker
anticoagulant and antiprotease activities compared to OMH and PMH. The neutralization
profiles of all heparins were comparable at the same concentrations. Studies in platelet
based systems showed that the HIT antibody interactions among heparins from different
species were comparable. In Vivo studies in animal model showed that, the anti-Xa and
anti-IIa effects of OMH and PMH were significantly stronger compared to BMH after IV
administration. However, BMH showed significantly longer half -life (T1/2) compared to
PMH and OMH with no major variations in AUC, Vd and CL parameters between each
agent.
In conclusion, these studies show that OMH and PMH are biosimilar and can be
developed as such for clinical purposes. The bovine derived heparins exhibited slightly
weaker potencies in functional assays despite comparable molecular profile. Potency
adjustment for in vivo usage may be required to obtain comparable anticoagulant
responses for the BMH. Soon, BMH and OMH may fill an unmet need not only for the
Eastern world but also for Western countries as a potential alternate source of heparin.

xxi

CHAPTER ONE
REVIEW OF LITERATURE
Hemostasis & Coagulation
Blood carries oxygen and nutrients to the various tissues of the body through a
complex network of blood vessels. Injuries of blood vessels may cause disruption to
the integrity of our vascular system. The ability of the body to respond to such an
injury is known as hemostasis. Hemostasis is the process by which blood changes
from a liquid to a gel, forming a clot to stop bleeding and to keep the blood within a
damaged vessel. This process involves vascular constriction, platelet plug formation,
and coagulation of the blood.
Vascular constriction, or vasoconstriction, is the first response to a blood
vessel injury. Many factors are involved in vasoconstriction including direct injury to
the vascular smooth muscle, reflexes initiated by local pain receptors, and chemicals
released by endothelial cells and platelets such as von Willebrand factor, ADP, and
thromboxane. Vasoconstriction alone can significantly reduce blood loss for 20-30
minutes, providing time for the formation of a platelet plug and blood clot. Various
platelet adhesive proteins and activators participate in platelet plug formation. Von
Willebrand factor (vWF) is a platelet adhesive protein which interacts with other
adhesive proteins and activators like collagen, factor VIII, and other clotting factors.
Circulating platelets bind to collagen via the glycoprotein Ia/IIa receptors located on
their surface. Additional circulating vWF further strengthens this adhesion by forming
1

2
additional links between the platelets and the collagen fibrils. This adhesion
process activates the platelets (Sakariassen et al., 1979).
Platelets contain two different storage granules, α and β (dense). The α storage
granules contain platelet derived growth factor (PDGF), fibrinogen, fibronectin,
platelet factor 4 (PF4), β-thromboglobulin, thrombospondin-1, factor V, platelet
activating factor (PAF), and von Willebrand factor (vWF) (Kaplan et al., 1987). The β
granules contain ADP, ATP, histamine, calcium, and serotonin (5-HT ) (Verhoeven
2

et., 1987). Once platelets are activated, the contents of α and β granules can be
released. The contents of these granules cause various actions such as further platelet
aggregation, activation of additional circulating platelets, and promotion of
coagulation. Aggregating agents, or agonists, found in the circulation, as well as those
released from the platelets themselves, induce further release of the platelet storage
granule contents. Some of these agonists include ADP, collagen, thrombin,
thromboxane (TXA ), PAF, serotonin, epinephrine, fibrinogen, and immune
2

complexes (Packham, 1994).
Platelet membranes express a variety of receptors for several agonists
including, the TXA receptor, the 5-HT receptor, α -adrenergic receptor, and the
2

2

2

thrombin receptor. Additionally, a number of glycoproteins also present on the
membrane surface serve as receptors for vWF (GP Ib), collagen (GP Ia/IIa),
fibronectin (GP IIb/IIIa), and fibrinogen (GP IIb/IIIa) (Hourani et al., 1991).
After platelets activate, they begin to aggregate on the injury site through
fibrinogen bridges, which link glycoprotein IIb/IIIa receptors located on adjacent
platelets. These aggregating platelets create a platelet mesh or plug. Although the
platelet plug initially arrests blood loss, a fibrin based clot is necessary in order to

3
stabilize the mesh and allow it to survive the sheer force of blood flow. This occurs
with the help of the coagulation system.
Coagulation is a complex process consisting of the extrinsic, intrinsic, and
common pathways. The extrinsic pathway, or tissue factor pathway, is activated when
the endothelial lining of blood vessels is damaged, which can result from a cut, other
abrasive injuries, or even the rupture of atherosclerotic plaques (Davie, et al., 1991.
The opening in the injured vessel wall exposes tissue factor (TF), a cell surface
glycoprotein, to flowing blood. TF is expressed by sub-endothelial cells, cells
surrounding blood vessels, which are not normally exposed to circulating blood and
white blood cells (WBC). TF is the cell surface receptor for the serine protease factor
VIIa (FVIIa). Exposure of TF to blood allows for the formation of an activated
TF/FVIIa complex. This TF/FVIIa complex then converts the inactive protease FX
into the active protease FXa (Davie, et al., 1991.
On the other hand, an amplification waterfall activates the serine proteases of
the intrinsic (contact) pathway. Activation of the contact pathway is initiated with the
formation of a complex composed of high-molecular-weight kininogen (HMWK),
prekallikrein, and factor XII (FXII) on a collagen backbone (Kaplan et al., 1987).
Both prekallikrein and FXII are converted to their active forms by the formation of
this complex. FXIIa then converts FXI into FXIa, which then activates FIX. Factor
IXa, along with its co-factor FVIIIa, form the tenase complex with the substrate, FX.
The formation of this complex leads to the activation of FX to FXa.
Both the extrinsic and intrinsic pathways of coagulation converge at the
common pathway and cause the activation of FX to FXa (Figure 1). Factor Xa is the
final enzyme required for the conversion of prothrombin to its active form, thrombin.

4
Activation of one molecule of FX leads to activation of thousands of prothrombin
enzymes. This process occurs when FXa complexes with its co-factor, factor V, and
Ca2+on a phospholipid surface to form the prothrombinase complex (Davie, et al.,
1991). Thrombin, or FIIa, is undoubtedly the most important enzyme in the
coagulation cascade. Thrombin’s most critical function in the coagulation cascade is
the conversion of soluble fibrinogen into insoluble strands of fibrin which are the
building blocks for the hemostatic plug or mesh. However, thrombin has many other
functions that are also important for maintaining hemostasis. Firstly, thrombin acts to
convert factor XI to XIa, VIII to VIIIa, and V to Va; these are positive feedback
mechanisms by which amplification of the cascade can occur. Secondly, thrombin can
also activate factor XIII to XIIIa (FXIIIa) which increases the stability of the fibrin
clot by crosslinking fibrin polymers. Finally, thrombin promotes platelet activation
and aggregation by activating protease-activated receptors on platelet membranes.
Fibrinogen is a plasma glycoprotein that is converted by thrombin into fibrin
during the coagulation process. Cleavage of fibrinogen by thrombin results in the
conversion of fibrinogen to fibrin and the consequent formation of a fibrin clot. Both
fibrinogen and fibrin have various roles in coagulation, fibrinolysis, and inflammatory
responses (Mosesson et al., 2005). These functions are regulated by interactive sites
on fibrin/fibrinogen that are unmasked by the conversion of fibrinogen to fibrin
(Mosesson et al., 2005). Fibrinolysis is a process that results in the removal of the
fibrin-based clot, leading to fibrin degradation products and clot lysis. This process
occurs following the conversion of plasminogen to plasmin by tissue-type
plasminogen activator (tPA). Fibrinolysis is important for the restoration of normal
blood flow.
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Figure 1. The coagulation cascade consists of several different zymogens, cofactors,
and inhibitors. There are two primary pathways, the intrinsic and extrinsic, which lead
to the common pathway and, ultimately, the activation of thrombin. Thrombin
converts fibrinogen to fibrin forming a clot. In addition, thrombin converts factor XIII
to factor XIIIa, which stabilizes the fibrin clot.
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Heparin background
Heparins discovery
Heparin was first used in the early 20th century as an anticoagulant. The
controversy surrounding its discovery stems back to 1916 when a medical student
named Jay McLean isolated a fat soluble anticoagulant compound (phosphatides)
from the dog livers. This took place in the laboratory of William Henry Howell
(Couch, 1989; Marcum, 2000; McLean, 1959). In 1918, Dr. Howell termed this
assumed phosphatide “heparin” to reflect its origin (Fye, 1984; Marcum, 2000).
However, by 1922, Dr. Howell’s research determined that heparin was actually a
carbohydrate and not a phosphatide as originally assumed (Howell, 1928). That same
year, heparin became commercially available by a company known as Hynson,
Westcott & Dunning (Fye, 1984). In the early 1930s, Howell began studying the
effects of heparin in humans and those studies were continued throughout the 1930s
by other laboratories (Fye, 1984). Until today, heparin continues to be used for the
treatment and prophylaxis of a variety of thrombotic related diseases (Richard
Norman, 2011).
Unfractionated heparin (UFH) belongs to a family of long unbranched
polysaccharides known as glycosaminoglycans (GAGs). UFH is highly ionized
(strongly acidic) and has the highest negative charge density of any known biological
molecule. It is comprised of repeating units of sulfated glucosamine and uronic acid
(either iduronic or glucuronic) connected by 1 – 4 linkages. The major sites of
sulfation are the 2-N and 6-O positions on glucosamine residues and the 2-O position
on iduronate residues. The mean degree of sulfation is about 2.0-2.5 per disaccharide
unit (Razi and Lindaht, 1995).
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UFH is comprised of components that vary in molecular weight from 2 – 40
kDa. It is a heterogeneous polymer with several different biological functions,
including inhibition of blood coagulation, inhibition of platelet aggregation, release of
tissue factor pathway inhibitor, and plasma clearing effects.
Structure of heparin

Figure 2. (A) Heparin composed of repeating disaccharide units of D-glycosamine
and uronic acid linked by 1→4 interglycosidic bonds. The uronic acid residue could
be either D-glucuronic acid or L-iduronic acid. (B) is the pentasaccharide sequence
required for antithrombin binding (AT).
Heparin sources
Heparin (UFH) is manufactured from either lung or intestinal animal
mucosa. It is now primarily sourced from porcine intestines rather than from
canine livers. In the past, bovine lung and ovine intestines were also alternative
heparin sources (Fu et al., 2013). Porcine intestinal heparin officially replaced
bovine lung heparin after the adoption of the 3rd International Standard by the
World Health Organization in 1973, which dictated heparin to be porcine mucosal
in origin (Mulloy et al., 2000). The use of ovine and bovine heparins is fairly
limited around the world. The main use of bovine lung and intestinal heparins is in
the Middle East, whereas ovine intestinal heparin has been used in Asia (Jasper et
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al., 2015). Porcine intestinal heparin is now used by the rest of the world. This
shift towards the use of porcine intestinal heparin was primarily due to concerns
of bovine spongiform encephalopathy (BSE) and scrapie through the parental use
of heparin derived from infected animals. Recently, there have been attempts to
generate bioengineered heparin. A biosynthetic pathway that begins with bacterial
synthesis of the backbone structure has been designed by some pharmaceutical
organizations. To convert the extracted and purified heparosan to heparin, a series
of chemoenzymatic modifications are performed to the polysaccharide backbone
(Restaino et al., 2013).
Because porcine heparin is primarily used around the world, the risk of
shortages and the cost of heparin has increased. (Fu, L., et al., 2013). Moreover,
due to cultural and religious reasons in some countries, there is a large demand for
alternative sources of heparins. Worldwide, it is estimated that there are 1.4 billion
cattle, 1.9 billion sheep and goats, and 980 million pigs. With advances in
technology and manufacturing processes, higher quality bovine and ovine
heparins are now available. Additionally, biological contaminants such as BSE
can be eliminated. Currently, bovine and ovine heparins are used in various parts
of the world and have been shown to exhibit similar biological and clinical
profiles (Jasper, J.P., et al 2015). The US FDA and other regulatory agencies are
currently reviewing the possibility of substituting porcine heparin with heparin
from other sources. Several Brazilian and Chinese manufacturers produce bovine
and ovine heparins for clinical use. Bovine and ovine heparins have the potential
to fill an unmet need not only for people with religious constrains but may also
provide an alternate source of heparin in worldwide.
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Heparin uses
In 1937, heparin was determined to be highly effective in preventing
postoperative thrombosis (Crafoord, 1937). Later, indications were extended to the
treatment of established venous thrombosis and pulmonary embolism (Barritt et al.,
1960). Currently, it is used to prevent blood clots after surgery, during dialysis, and
during blood transfusions. The main clinical indications for heparin are in the
prevention and treatment of arterial and venous thromboembolism, thrombotic stroke,
and in certain types of coronary artery syndrome, mainly unstable angina (Hirsh et al.,
2001). Heparin has well-known common side effects such as bleeding, heparininduced thrombocytopenia (HIT), and, to a lesser extent, skin necrosis and
osteoporosis (Gray et al., 2008).
Heparin mechanisms of action
UFH mainly mediates its anticoagulant effect through antithrombin (AT). In
1939, heparin was shown to mediate its biological functions through a plasma protein,
known at that time as heparin cofactor. The suggestion that heparin cofactor may
actually be antithrombin (AT) was made in the 1950s by Seegar at Wayne State
University and Fitzgerald at MIT (Petitou, 2003). It was not until 1968 when
Abildgaard (1968) isolated the plasma component, that the heparin cofactor was
renamed antithrombin (Verstraete, 1990). Rosenberg and his colleagues then
confirmed that AT was indeed the true heparin cofactor (Rosenberg et al., 1973;
Rosenberg, 1975).
AT is a globular glycoprotein produced by the liver that consists of 432
amino acids with a molecular weight of 58 kDa (Choay, 1989). It is a serine protease
inhibitor (SERPIN) and is considered one of the most important anticoagulant
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molecules in mammalian circulatory systems. The main targets of AT are thrombin
and factor Xa; however, AT can inhibit several other serine proteases including IXa,
XIa, XIIa, kallikrein, and plasmin. AT binds thrombin in a 1:1 stoichiometric
complex (Rosenberg et al, 1973). The presence of heparin causes an approximate
1000-fold increase in the rate of thrombin inactivation by AT (Bary et al., 1989). The
interaction between AT and heparin (Figure 3) is dependent on a well-defined unique
pentasaccharide sequence within heparin (Choay et al., 1983; Walenga et al., 1988;
Petitou et al., 2003). The AT/heparin interaction produces a conformational change in
the structure of AT. This change enables additional interactions between AT and
heparin, resulting in a stronger binding (Pike et al., 2005). After the complex is
formed, the AT interaction reverts to low-affinity binding resulting in the release of
heparin from the covalent AT–factor Xa complex.
Thrombin inhibition occurs through a template mechanism of activation,
whereby both AT and thrombin bind adjacently on the same heparin chain. Lane et al.
(1984) demonstrated that a minimum heparin chain length of 18 saccharides (the
pentasaccharide sequence and an additional adjacent 13 saccharides) is required for
thrombin inhibition by AT. Negative charges available at the extended heparin
polysaccharide units bind non-specifically to the exosite (positively charged region)
of thrombin (Olson et al., 1992; Quinsey et al., 2004). A strong ternary complex
between AT, thrombin, and heparin is formed. This complex produces a substantial
increase in the rate of inhibition of thrombin. Due to the random distribution of the
pentasaccharide sequence in heparin, lower MW fragments of heparin are not be able
to bind to or inhibit thrombin. Thus, heparin chains in the MW range of 5 – 10 kDa
have a progressive increase in thrombin inhibitory activity (Gray et al., 2008).
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Besides interactions with AT, heparin can also interact with another SERPIN
known as heparin cofactor II (HCII). HCII has considerable sequence homology to
AT. HCII consists of a single-chain glycoprotein which is 480 amino acids in length
(Tollefsen, 1995). Unlike AT, HCII can only inhibit thrombin, with which it forms a
1:1 stoichiometric complex (Tollefsen et al., 1982). Moreover, HCII can inhibit the
proteolytic enzyme, chymotrypsin (Griffith et al., 1985). Heparin catalyzes the
formation of the HCII-thrombin complex, which increases the rate of thrombin
inhibition ~1000-fold (Tollefsen et al., 1981; Tollefsen et al., 1982; Griffith et al.,
1985).
Heparin also releases tissue factor pathway inhibitor (TFPI). TF is the main
mediator by which thrombin generation is initiated in response to vessel damage
(extrinsic pathway) (Mackman, 2006). TF is a 45 kDa transmembrane glycoprotein
which is located at extravascular sites that are not normally exposed to the blood
(Maroney et al., 2008). Heparin has been shown to release the pool of TFPI that is
bound to glycosaminoglycan on the surface of the endothelium (Sandset et al., 1988).
Additionally, heparin also upregulates TFPI gene expression which causes the
elevation of both plasma and cellular TFPI pools (Crawley et al., 2008).
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Antithrombin/ Heparin binding
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Figure 3. The main targets of AT are thrombin and factor Xa of the coagulation
cascade. The interaction between AT and heparin is dependent on a well-defined
unique pentasaccharide sequence within heparin. The AT/heparin interaction
produces a conformational change in the structure of AT, enabling additional
interactions between AT and heparin, resulting in stronger binding. The strong
inhibition of thrombin is due to a template mechanism of activation, whereby both AT
and thrombin bind adjacently on the same heparin chain. A minimum heparin chain
length of 18 saccharides is required for thrombin inhibition by AT. The AT/heparin
interaction produces a conformational change in the structure of AT. This
conformational activation mechanism promotes binding of AT to the active site of
factor Xa.
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Heparin structural analysis
Heparin has a complex molecular structure. The chemical profile plays a
pivotal role in determining the biological activity of heparin (Barrowcliffe 1995).
Various laboratory methods have been developed to analyze the structural elements of
heparin. These include: gel permeation chromatography, scanning UV spectroscopy,
heparinase digestion, mass spectrometry, and nuclear magnetic resonance
spectroscopy. All are useful tools to understand the underlying structure-activity
relationship of heparins.
The molecular weight of heparin is one of the most important determinants for
its biological activity and bioavailability (Emanuele and Fareed, 1987). Gel
permeation chromatography high performance liquid chromatography (GPC-HPLC)
is usually used to determine number average molecular weight (Mn), weight average
molecular weight (Mw), and polydispersity (Ahsan et al, 1994). Additional methods
such as viscometry, ultracentrifugation, and gradient polyacrylamide gel
electrophoresis (PAGE) can be used for further analysis of the molecular weight
profile of heparin (Linhardt et al. 1988).
High-resolution analysis of heparin structure has relied on spectroscopic
methods such as proton (1H) and carbon (13C) nuclear magnetic resonance (NMR)
spectroscopy (Casu and Torri 1999.). NMR spectroscopy is used to determine the
ratio of iduronic acid to glucuronic acid, the content of N-acetyl-glucosamine, and the
patterns and degree of sulfation. Considering its wide breadth of analysis NMR
spectroscopy has emerged as an indispensable method for the detection and
identification of both structural heterogeneities within and between heparin samples,
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as well as for the detection and identification of contaminants (Monakhova et al.,
2015).
Heparin pharmacokinetics
Unfractionated heparin is a heterogeneous mixture of polysaccharide chains of
varying length. It is usually administered by continuous IV infusion or SC injection.
To overcome the low bioavailability associated with the SC route, a higher initial
dose of heparin is required (Hull et al., 1986). After bolus IV injection, UFH has a
half-life of approximately 1-2 hours (Eikelhoom and Hankey, 2002), a volume of
distribution of 40-70 ml/kg (Spruill et al., 2001), and it is eliminated from the blood
exponentially (Blombäck et al., 1963). Such first-order kinetics would ordinarily
suggest a constant half-life of the drug, which is independent to the amount of drug
injected. However, it is well known that the half-life of UFH increases in relation to
the dose administered.
Heparin clearance occurs through the kidney and it is a combination of slower
first-order mechanism and a rapid saturable phase through binding to receptors on
endothelial cells (Glimelius et al., 1978) and macrophages where it is depolymerized.
Heparin neutralization
Protamine sulfate (PS). In 1868, protamine was identified by Friedrick
Miescher as a nitrogenous base bound to nuclear material of Rhine salmon sperm
heads. In 1937, Chargraff and Olsen demonstrated that protamine sulfate could
neutralize the anticoagulant action of heparin (Chargaff et al., 1937). Today,
protamine is usually commercially prepared from salmon milt into a dried powder or
solution. It has the ability to reverse the anticoagulant activity of heparin. Protamine
is arginine-rich (nearly 67%) and strongly basic, Small nuclear proteins (45kDa)
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replace histones late in the haploid phase of spermatogenesis and are believed to be
essential for sperm head condensation and DNA stabilization (Zhou et al., 2013).
Protamine has a mild anticoagulant effect when administered alone. However,
when it is given in the presence of heparin (which is strongly acidic), ionic forces
form a stable precipitate. In this stable precipitate an intermolecular charge
neutralization occurs, thereby causing the neutralization of heparin activity (Adkins et
al., 1967). Various factors influence the interaction of protamine and heparin
including individual molecular weight of a given protamine or heparin, charge type,
and charge density (Moss et al., 1986). Heparin’s affinity for protamine is directly
influenced by many factors such as molecular weight, degree of sulfation, and
position of sulfate residues on the heparin chain (Dawes et al., 1982). Dawes and
Pepper (1982) determined that degree of sulfation is the most important determinant
of heparin’s affinity to protamine. The binding of protamine to heparin most likely
dissociates heparin from AT, thereby breaking the heparin/AT complex and
neutralizing heparin’s anticoagulant activity (Okajima et al., 1981).
Other agents that have been evaluated for their ability to neutralize UFHs
including polybrene and PMX60056. Polybrene (hexadimethrine bromide), a
quaternary ammonium polymeric salt, is a synthetic heparin antagonist used in
clinical laboratories to neutralize the anticoagulant effects of heparin as well as to
determine heparin activity in human plasma (Montalescot et al., 1990). PMX 60056
(PolyMedix Inc., Radnor PA) is the clinical lead compound of a series of small
molecule oligomers that interact strongly with heparin and LMWHs.
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Platelet factor 4 (PF-4). Platelet factor 4 (PF-4) is a natural antagonist of
heparin. PF-4 has a mean molecular weight of 7.7 kDa and is 70 amino acids long. It
is synthesized by megakaryocytes and stored in the alpha granules of platelets (Barber
et al., 1972). PF-4 is released from platelets by thrombin in the form of a high
molecular weight PF-4 tetramer, acomplex with two chondroitin sulfate proteoglycan
molecules (Barber et al., 1972). The moment it is released, it is capable of
neutralizing the anticoagulant effects of heparin in plasma (Kaser-Glanzmann et al.,
1972). The tetrameric form of PF-4 is essential for the high affinity heparin binding
(Mayo et al., 1989).
Similar to the case of heparin’s inhibition of thrombin, a heparin chain length
greater than 18 saccharides is required for optimal PF-4 binding (Lane et al., 1984).
Heparin molecules above 18 saccharides with both anti-thrombin and anti-factor Xa
activities can be completely neutralized by PF-4, whereas molecules below 18
saccharides, which retain anti-factor Xa activity, are more resistant to neutralization
by PF-4. A weaker neutralization by PF-4 has been seen for LMWHs in comparison
to that of heparin (Lane et al., 1984).
One manifestation of heparin’s interactions with platelet factor 4 is its ability
to cause heparin induced thrombocytopenia (HIT). HIT is characterized by a severe
decline in platelet count (>50%) in association with new thromboembolic
complications (Chong B. H. 2003).
When PF-4 is released from platelets it binds to heparin, resulting in a
conformational change in PF-4. This complex is considered a foreign antigen within
the body and may be immunogenic. The immune response is characterized by initial
IgM antibody formation, and followed by the development of IgG antibodies on the
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5th day (Warkentin, 1998). The IgG antibodies form a complex with heparin and PF-4
in the bloodstream. The tail of the IgG antibody binds to the Fc receptor on the
surface of platelets leading to their activation. These activated platelets have a
markedly shortened survival and are acutely consumed in prothrombotic processes,
resulting in thrombocytopenia. HIT generally occurs 5 to 14 days after initiation of
heparin therapy (Warkentin, 1998).
Low molecular weight heparin (LMWH)
Although UFH is the cornerstone of treatment of various thrombotic diseases,
including VTE, DVT, and PE, it exhibits some pharmacologic disadvantages.
LMWHs are an important alternative to UFH with several advantages, such as higher
bioavailability, enhanced safety (less bleeding), greater convenience (fewer
injections), and better efficacy (lower rate of thrombotic events). Some of the most
common commercially available LMWHs are enoxaparin sodium, dalteparin sodium,
tinzaparin sodium, ardeparin sodium, and second-generation LMWH, bemiparin
sodium (Dietrich et al., 1999).
LMWHs are produced by controlled enzymatic or chemical depolymerization
of UFH either by heparinase, a combination benzylation followed by alkaline
hydrolysis, nitrous acid degradation, or peroxidative cleavage (Weitz 1997). The
different methods produce LMWHs with different biochemical and pharmacological
profiles. Therefore, LMWHs are not interchangeable unless parallel clinical trials
have been performed for each specific clinical indication (Bick et al., 2005).
LMWHs consist of short chain polysaccharides, which are approximately onethird the size of UFH (Fareed et al., 1998). LMWHs are defined as heparin salts
having at least 60% of all chains with a molecular weight less than 8.0 kDa. On
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average, LMWHs have molecular weights ranging between 3.5 to 6.5 kDa (Gray et
al., 2008).
Because of their lower molecular weight, LMWHs have several distinct
characteristics from UFH. Firstly, in contrast to UFH, which has an anti-FXa/anti-FIIa
ratio equal to 1, LMWHs have a ratio which is greater than 1. This ratio generally
increases as the molecular weight of the compound decreases (Gray et al., 2008). A
greater anti-FXa/anti-FIIa ratio denotes a reduction in bleeding, which is often a side
effect of UFH. Secondly, having smaller molecular weight components means
LMWHs are better absorbed following subcutaneous administration. While UFH has
a bioavailability of approximately 20 to 30 percent (Fareed, 1985), LMWHs are
virtually 100 percent bioavailable after subcutaneous injection (Weitz, 1997).
Moreover, the plasma half-life of LMWHs is two to four times longer than that of
UFH; however, this is dependent on the dose, route of administration, and assay used
to detect the anticoagulant activity (Fareed et al., 1985). LMWHs are a more
predictable anticoagulant because they have a decreased propensity to bind to plasma
proteins, macrophages, and endothelial cells in comparison to UFH. Consequently,
LMWHs are less likely to cause heparin-induced thrombocytopenia (HIT) (Baroletti
et al., 2008), can be administered once daily, and do not require continuous
monitoring.
Currently, various generic versions of LMWH are available in the market.
Compared to their branded counterparts, these agents are cheaper. Many works of
literature have shown that generic LMWHs not only exhibited similar structural
composition but also exhibited comparable anticoagulant and antiprotease activities
when compared to their branded counterparts (Maddineni et al., 2006).
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(ULMWHs) have been developed as a response to trying to produce safer and
more efficacious heparin and LWMHs. ULMWHs are obtained by a selective and
controlled depolymerization of heparin and have mean molecular weights ranging
between 2-3 kDa. ULMWHs mainly act through the inhibition of the coagulation
enzyme factor Xa and, to a lesser extent, factor IIa (thrombin).
Animal-sourced low–molecular weight heparins are widely used to treat
various clotting disorder. Because it is poorly controlled, and its anticoagulant activity
is not fully reversible by protamine, a synthetic homogeneous oligosaccharide can be
used as a replacement. Dodecasaccharide is a synthetic homogeneous oligosaccharide
with MW of 3.5 (kDa). It has high affinity to antithrombin and exhibits anti-Xa
activity along with very weak anti-IIa actions which are comparable to LMWHs. In
vitro and ex vivo experiments have shown that the anticoagulant activity of
dodecasaccharide can be reversed by protamine. (Xu et al., 2017).
Bioheparins
Currently, the heparin used both in the manufacturing of LMWHs and
clinically reply upon livestock animal tissues. The variability of animal-sourced
heparin and heparin sulfates their inherent impurities, the limited availability of
source tissues, and the poor control of these source materials and their manufacturing
processes, all suggest a need for new approaches to their production. Over the past
decade, there have been major efforts in the biotechnological production of
glycosaminoglycans, such as mitrin from plants and bacteria. Mitrin is a chemically
engineered anticoagulant polysaccharide prepared from Escherichia coli K5
polysaccharide to replace heparin (Kuberan et al., 2003). Casu and coworkers
described the generation of a series of heparin-like products through regioselective
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sulfation of the capsular polysaccharide from Escherichia Coli K5 (Casu et al., 1994).
The capsular polysaccharide from E. coli has the same basic structure as heparin
[→4)-β-D-GlcA-(1→4)-α-D-GlcNAc-1(1→].
The polymeric backbone known as N-acetyl heparosan provides a novel
starting material to develop semi-synthetic heparin-like molecules. To accomplish
this, the bacterial polysaccharide is first converted to sulfaminoheparosan by
deacetylation (through hydrazinolysis) followed by N-sulfation. Controlled Osulfation of this product results in the generation of a series of novel heparin-like
oligosaccharide mixtures with varying O-sulfation patterns and anticoagulant
activities. This sulfated oligosaccharide also shows varying degrees of binding to AT
due to the presence of 3-O- sulfated glucosamine unit. Thus, utilizing these semisynthetic approaches, anticoagulants with structural identities distinct from heparin,
yet with similar interactions with HC-II and AT, can be developed. These bacterial
polysaccharide derivatives interact with AT and promote its anticoagulant action in a
manner similar to that of heparin (Razi et al., 1995). Depending on the reaction
conditions during their preparation, the products showed different proportions of
components with high affinity for AT. A high affinity fraction of this bacterial
polysaccharide was shown to cause conformational changes in the AT molecule very
similar to those induced by high-affinity heparin. The compositional analysis of these
polysaccharide fractions revealed that they have the AT binding site, the 3-O sulfated
GlcN unit, which has previously been identified as the marker component of the AT
binding pentasaccharide sequence in heparin. Due to the charge density of these
agents, they may also share other biological activities with heparin including
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endogenous release of mediators such as TFPI, modulation of adhesion molecules,
interaction with endothelial cells and anti-inflammatory effects.
Therefore, a substitute for both UFH and LMWHs may be semisynthetic heparinlike anticoagulants. Furthermore, semisynthetic heparin-like anticoagulants can be
structurally modified by chemical or enzymatic methods to achieve drugs with
desirable biochemical and pharmacological profile. It is expected that these agents
will exhibit all the biological actions that are associated with heparins (Fu, L. et al.,
2016).

CHAPTER TWO
STATEMENT OF PURPOSE
Unfractionated heparin (UFH) is one of the oldest drugs that is still in clinical use.
UFH is the most widely used anticoagulant drug for the surgical and interventional
indications. Unfractionated heparin and low molecular weight heparin (LMWHs) are
widely used for the management of thrombotic and cardiovascular disorders. Most of the
heparins are derived from pig mucosa (porcine mucosa). However, heparin has also been
manufactured from other mammalian sources such as bovine (cow) and ovine (sheep).
Although most of the heparins used globally are obtained of porcine origin, bovine and
ovine heparins have also been used in non-Western markets. The North American and
European community primarily use heparins derived from porcine sources, which are
primarily of Chinese origin. Worldwide there are 1.4 billion cattle, 1.9 billion sheep and
goats and 980 million pigs. Both cow and sheep provide alternate sources of heparin
which are not widely used due to regulatory reasons. Currently there are some concerns
about the shortage of the porcine heparins as they are widely used in the manufacturing
of the low molecular weight heparins (LMWHs). Also, open-heart surgeries,
hemodialysis and intervention cardiovascular procedures are usually carried out with
anticoagulants and unfractionated heparins. Moreover, due to cultural and religious
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reasons in some countries, alternative sources of heparins are needed. The FDA is
currently considering the introduction of bovine and ovine unfractionated heparins.
With the advances in technology and manufacturing processes, higher quality
bovine and ovine heparins are now available. In addition, the biologic contaminants such
as bovine spongiform encephalopathy (BSE) are eliminated. Currently bovine and ovine
heparins are used in various part of the world and have been shown to exhibit similar
biologic and clinical profiles. Several Brazilian and Chinese manufacturers provide
bovine and ovine heparins for clinical use.
UFHs produce their effects via interactions with various endogenous proteins
such as antithrombin (AT) and heparin cofactor II (HCII). UFHs mechanism of action
relies in large part to specific pentasaccharide sequence that enables binding to
antithrombin. This binding results in a conformational change in antithrombin that
facilitates inactivation of thrombin (Factor IIa) and Factor Xa, leading to a significant
increase in anticoagulant activity. The degree to which these compounds exert their
effects through AT and HCII, as well as other endogenous proteins, determines how well
they inhibit various targets of the coagulation system and the severity of side effects.
The primary purpose of this dissertation was to determine the extent of
biosimilarity between BMH, OMH and PMH. For this investigation, ten batches of each
heparin source were utilized. Their activities in biochemical and biological assays were
compared in order to elucidate how their molecular composition and structural attributes
affect their pharmacological actions.
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Ten batches of PMH obtained from Medefil Inc., USA, were used throughout this
dissertation. The average molecular weight of these batches was 18.5 kDa. Ten batches of
BMH obtained from KinMaster Pharmaceutical, Brazil, were selected for this study. The
average molecular weight of these batches was 21 kDa. Ten batches of OMH obtained
from Ronnsi Pharmaceutical, China, were used throughout this dissertation. The average
molecular weight of these batches was 17 kDa. All agents were stored in a desiccator at
room temperature (20 – 25 ºC).
This dissertation is focused on delineating the pharmacological actions of various
heparins by understanding their molecular composition and structural attributes. To
investigate these claims, the following three specific aims were addressed:
Specific Aim 1:
•

To compare the molecular weight and structural profiles of bovine,
ovine and porcine mucosal heparins.

Specific Aim 2:
•

To compare the functionality of bovine, ovine and porcine mucosal
heparins in terms of their USP potency, global anti-coagulant and
anti-protease activities.

Specific Aim 3:
•

To compare the pharmacodynamics profile of bovine, ovine and
porcine mucosal heparins following I.V. administration to non-human
primates.
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Significance
Although heparin has provided a universal anticoagulant option with wide spread
usage as a surgical anticoagulant, it has some other pharmacological properties which are
not fully understood. Initial supply of heparins was primarily obtained from mammalian
tissue and source verification was not required. The currently used heparin is mainly
obtained from porcine mucosa. Heparins from other sources such as bovine lung, bovine
mucosa, or sheep mucosa are not available for clinical use in the USA. Heparins from
these sources are available in pharmaceutical quantities and such preparations are
available in Asian and African countries. Given the number of cattle and sheep, large
quantities of heparins can be obtained. This thesis provides a comprehensive account of
the structural and biological actions of heparins obtained from bovine, ovine and porcine
sources. It also demonstrates the biosimilarity between these heparins and an approach to
equate their potency in valid functional assays which can potentially deem them
interchangeable. This study has demonstrated that, despite microchemical differences in
the degree of sulfation and other compositional variables, heparins obtained from porcine
and ovine sources are almost identical. The AT binding regions, which facilitates the
interaction between heparin and antithrombin, are comparable in porcine and ovine
mucosal heparins. However, BMH shows considerably lower AT affinity. Despite this,
the potency of BMH can be adjusted to exhibit comparable biological effects to OMH
and PMH. This dissertation provides a stepwise approach to compare heparins from
different animal sources and to adjust their potencies utilizing the USP reference or a
comparable reference heparin.

CHAPTER THREE
MATERIALS AND METHODS
Materials
Anticoagulants
Porcine mucosal heparin (PMH). Ten samples of porcine mucosal heparin
obtained from Medefil Inc., USA, were used throughout this dissertation. These agents
were stored in a desiccator at room temperature (20 – 25 ºC).
Bovine mucosal heparin (BMH). Ten samples of bovine mucosal heparin
obtained from KinMaster Pharmaceutical, Brazil, were used throughout this dissertation.
These agents were stored in a desiccator at room temperature (20 – 25 ºC).
Ovine mucosal heparin (OMH). Ten samples of ovine mucosal heparin obtained
from Ronnsi Pharmaceutical, China, were used throughout this dissertation. These agents
were stored in a desiccator at room temperature (20 – 25 ºC).
The average molecular weight (Mw) of PMH, BMH and OMH batches were 18.5
kDa, 21 kDa and 17.5 kDa respectively as determined by high-performance liquid
chromatography (HPLC).
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Protein/Enzymes
Heparinase I. Heparinase I (EC 4.2.2.7) was obtained from IBEX
Pharmaceuticals, Montreal, Canada. This enzyme was purified from Flavobacterium
heparinum. Its molecular weight was reported to be 42.5 kDa. The potency was
designated as >80 IU/mg, where one international unit (IU) is defined as the amount of
enzyme that will liberate 1.0 mole of unsaturated oligosaccharides from porcine
mucosal heparin per minute at 30 ºC and pH 7.0 (Ernst et al., 1995). Purity of this
enzyme was determined to be greater than 90% by reverse-phase HPLC and SDS-PAGE
analysis. The material was provided as a solution and was stored at –70 ºC until use.
Protamine sulfate. Protamine sulfate was obtained from Choay Institute (Paris,
France) in powder form and reconstituted in normal physiologic saline at a concentration
of 100 µg/ml. It was produced from salmon sperm and had a specific activity of 138
UAH/mg. The mean molecular weight of this protamine as determined by HPLC was 4.0
kDa.
Antithrombin. Human antithrombin (AT) was obtained from Sekisui Diagnostics
(Stamford, CT) in vials containing 2.5 IU. The antithrombin was immunoaffinity purified
from pooled fresh frozen plasma by heparin-Sepharose chromatography and salt-gradient
elution. The product was stored at 4 ºC until it was reconstituted with 1 ml of saline.
Molecular weight profiling
The mobile phase used in all the HPLC studies was made using anhydrous
sodium sulfate (0.3 M Na2SO4, pH = 5.0) and HPLC-grade water from Sigma-Aldrich
Inc. (St. Louis, MO). Thirteen standard heparin fractions (Sanofi, Paris, France) ranging
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in molecular weight from 51.0 kDa to 2.4 kDa were used to calibrate the GPC-HPLC
instrument and to make the standard curve.
Chromogenic antiprotease BioMed kits
Heparin anti-Xa and anti-IIa USP kits were obtained from HYPHEN Biomed,
France. The anti-Xa and anti-IIa USP kits numbers were 221010 and 221025
respectively. These are chromogenic assays developed to measure heparins
concentrations in plasma or in purified solutions in terms of their anti-Xa and anti-IIa
activities.
Blood products
Blood bank plasma (BBP). Normal human CPDA-1 (citrate phosphate dextrose
adenine) plasma was obtained from the Blood Bank, Department of Pathology, Loyola
University Medical Center, Maywood, IL. This plasma was obtained from blood donated
by normal healthy human volunteers who tested negative for acquired immunodeficiency
syndrome (AIDS) and hepatitis B and C viruses. The fresh frozen plasma packs (n = 5),
not more than 30 days old, were thawed at 37 ºC, and then the pooled plasma was
aliquoted in volumes of 10 ml and refrozen at –70oC for a period of not more than two
months.
Normal monkey plasma (NMP). Primates (Macaca mulatta) were anesthetized
with ketamine (10 mg/kg, I.M.) and blood samples were drawn from the saphenous vein
using a 21-gauge ¾ inch butterfly needle and a 5 ml syringe. The blood was transferred
into a 4.5 ml sodium citrate (3.2%) BD Vacutainer® blood collection tube (Becton
Dickinson and Company, Franklin Lakes, NJ). Approximately 15 minutes later, the blood
was centrifuged at 4°C, 3,000 rpm (2,053 x g) for 20 minutes. Plasma from a minimum
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of 14 primates was pooled and aliquoted in 10 ml volumes. The pooled monkey plasma
(NMP) was frozen in plastic tubes at -70°C for not more than 2 months.
Major instruments
Major instruments used to perform various experiments reported in this
dissertation include a WatersTM high-performance liquid chromatography (HPLC) system
(Milford, MA). This was used to determine the molecular profile of the various
compounds. Nuclear Magnetic Resonance (NMR) spectroscopy was performed using a
Bruker 400 MHz and 600 MHz AVANCE III NMR spectrometer (Bruker, Germany). An
ACLTM Elite (Beckman-Coulter, Miami, FL) was used for antiprotease assays. A
SpectraMax® Plus384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale,
CA) was used to measure clot lysis, kinetics of various assays, and with the ELISA
method. PAP-8E from Bio/Data Corporation was used to measure the rate and extent of
platelet aggregation reactions.
Non-human primates
Male and female non-human primates (Macaca mulatta) (4 - 16 kg) were used for
the studies on the pharmacologic actions of heparins. The non-human primates are part of
a colony currently housed at the Loyola University Chicago Health Sciences Division
according to the institutional IACUC protocols of Loyola University Medical Center. All
experiments were non-terminal and approved by the Loyola University Chicago Health
Sciences Division IACUC (LU # 208582 (0.02); P/D # 032-16; IACUC # 16-040). The
primates were anesthetized using ketamine HCl (100 mg/ml) obtained from Webster
Veterinary (Devens, MA). Hematologic profiles and serum chemistry profiles were
performed at the Clinical Laboratory, Department of Pathology at Loyola University
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Medical Center using a Beckman Coulter LH 750 Hematology Analyzer (Beckman
Coulter Inc, Indianapolis, IN).
All animal studies were carried out in compliance with the guidelines set forth by
the Institutional Animal Care and Use Committee (IACUC), Loyola University Medical
Center and the Principles of Laboratory Animal Care (National Institutes of Health,
1985).
Methods
Physiochemical characterization of agents
Gel permeation chromatography. Molecular weight determinations were made
using GPC in a high-performance liquid chromatography (HPLC) system (Waters 845,
Millipore-Waters, Lexington, MA) equipped with Millennium 2000 software designed
for polymer analysis. The HPLC system consists of a computer, a LAC/E interface
module, two 510 HPLC pumps, a 712 WISP auto-injector, a 2404 differential refraction
index (RI) detector, and a 2487 ultraviolet (UV) tunable absorbance detector. The UV
and the RI detectors were linked in series, with the outlet of the joint columns (TSK
G3000SW and TSK G2000SW, TosoHaas, Tokyo, Japan) attached to the UV detector.
The molecular weight profile of each agent was determined using the method
reported by Ahsan et al. (1995). The system was equilibrated using freshly degassed
mobile phase (0.3 M sodium sulfate) until a stable baseline was obtained. Analysis was
carried out by injecting 20 μl of sample (10 mg/ml in 0.3 M sodium sulfate) into the
HPLC system. The flow rate for the mobile phase was 0.5 ml/min and the run time for
each sample was 65 minutes. The internal temperature for the RI detector was set at 35C
and UV detection was made at 205 nm.
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Following each run, the elution profile of each sample was analyzed by the
narrow range calibration (NRC) method (Ahsan et al, 1995; Ahsan et al, 1993). The NRC
method uses 13 calibrators ranging from 51.0 kDa to 2.4 kDa and requires the UV
detector to be set at a wavelength of 205 nm.
Calibration of the HPLC system was performed in a similar manner using the
narrow range calibrators (10 mg/ml calibrators in 0.3 M sodium sulfate) with welldefined molecular weights. The log molecular weight of each calibrator was plotted
against its retention time. Using the Millennium 2000 software, a third order polynomial
regression equation (Log MW = D0 + D1 (RT) + D2 (RT) 2 + D3 (RT) 3) was fitted to the
data points, where MW represents the calculated molecular weight, RT represents
retention time and D0, D1, D2 and D3 represent coefficients calculated in the curve fitting
process. The molecular weight profile of each agent was determined based on this
calibration curve. The molecular weight profile consists of such parameters as weight
average molecular weight, number average molecular weight, and polydispersity.
Nuclear magnetic resonance spectroscopy. Nuclear magnetic resonance (NMR)
spectroscopy was performed using a Bruker 400 MHz and 600 MHz AVANCE III NMR
spectrometer (Bruker, Germany) with a 5-mm inverse Z gradient probe. BMH, OMH,
and PMH pools were investigated. Deuterated water of 99.8% purity containing 0.1%
trimethylsilyl propanoic acid (TSP) as internal standard was purchased from Euriso-top
(Saarbrücken, Germany). Cs2CO3 (99.5%) was provided by Sigma Aldrich (Steinheim,
Germany). EDTA was obtained from AppliChem (Munich, Deutschland).
NMR measurements were performed on Bruker Avance III 600 MHz
spectrometer (Bruker Biospin, Rheinstetten, Germany) with BBO cryo probe equipped
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with Bruker Automatic Sample Changer (B-ACS 120) at 297 K. NMR spectra were
recorded with standard pulse program (zg30 in Bruker language) using 16 scans and 2
prior dummy scans (Monakhova, Y. B. et al., 2015). The data of 132k points were
acquired with a spectral width of 24.0155 ppm, a receiver gain of 72, an acquisition time
of 4.5438 s. The data were recorded automatically under the control of ICON-NMR
(Bruker Biospin, Rheinstetten, Germany). All NMR spectra were manually phased and
baseline-corrected using Topspin 3.2 (Bruker Biospin, Rheinstetten, Germany).
Global anticoagulant assays
Activated partial thromboplastin time (aPTT). The activated partial
thromboplastin time is a screening test for the intrinsic pathway of coagulation (factors I,
II, V, VIII, IX, X, XI and XII) and is commonly used for monitoring heparin therapy. It is
based on the measurement of time to clot after plasma has been activated by a platelet
substitute (purified phospholipids) plus added activator (micronized silica) and calcium
chloride.
The TriniCLOTTM APTT S kit (Trinity Biotech USA Inc, Jamestown, NY) was
used to determine the APTT of the test samples. The following reagents were included in
the TriniCLOTTM APTT S kit: TriniCLOT APTT CaCl2 (0.02 M) and TriniClOT APTT
S reagent. The reagent contains purified phospholipids (porcine and galline), micronized
silica (activator), stabilizer, and 0.02% sodium azide as preservative. All reagents were
kept refrigerated (4C) until use. Each vile of TriniCLOT APTT CaCl2 (0.02 M) and
TriniClOT APTT S reagent came ready to use.
When the assay was utilized for human or primate plasma, the assay was
performed as follows. An aliquot of 250 µl of each of the plasma samples were placed
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into individual test cups, which are then placed in an ACL test cup carousel in a defined
sequence. NHP or NMP and saline samples were included in every carousel as controls.
The reagents were placed in their appropriate positions (TriniCLOT APTT S reagent in
position 2 and CaCl2 in position 3). A clean ACL rotor was placed in the carousel. The
appropriate parameters were set on the machine before running the test. An aliquot of 100
µl of each of the plasma samples and 100µl of APTT reagent were incubated at 37°C for
5 minutes. After 5 minutes of incubation, prewarmed calcium chloride was added to
trigger coagulation and the clotting times were then measured on an ACL Elite
(Beckman-Coulter, Miami, FL). Measurement of clotting time was stopped at 300
seconds as clotting times beyond 300 seconds are outside of the linear range of the
instrument.
Thrombin time (TT). Thrombin time (TT) is a clot-based assay, which measures
the time it takes for thrombin to convert fibrinogen to fibrin after the addition of a known
amount of thrombin to plasma. Thrombin was obtained from Enzyme Research
Laboratories (South Bend, IN) and was reconstituted with 0.02 M CaCl2 to yield 5 U/ml
solution which gave a baseline clotting time of 9±1.8 seconds. Thrombin was kept frozen
at -70°C until use. The assay was performed as follows. 200 l of test plasma, calibration
curve or control was added to a test cup and incubated at 37 ºC. After three minutes, 100
l of 5 U/ml thrombin was added, and the clotting time was measured using ACL Elite.
Chromogenic antiprotease assays
Anti-factor Xa assay. The inhibition of factor Xa in human and primate samples
was performed on the ACL Elite fast kinetics coagulation analyzer (Beckman-Coulter,
Hialeah, FL), in the following manner. Test samples were prepared by placing 250 l of
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test plasma into individual test cups, which were then placed in an ACL-test cup-carousel
and their positions were recorded. Up to 40 plasma samples could be inserted into one
carousel. Normal human pool plasma and saline samples were included in every carousel
as controls. Bovine factor Xa (1.0 mg/ml) (Enzyme Research Laboratories, South Bend,
IN) was reconstituted with 4 ml (final factor Xa concentration of 6µg/ml) of Xa/IIa buffer
(50mM Tris, 175 mM NaCL, 7.5 mM Na2 EDTA, 800 mls distilled H2O, pH = 8.4, 25
ºC) prior to use. The substrate, Spectrozyme FXa (5 µM) (Sekisui Diagnostics, Stamford,
CT) was reconstituted by adding 2 ml of distilled water. The reagents were placed in their
appropriate positions (bovine factor Xa in position 2 and Spectrozyme FXa in position 3).
A clean ACL rotor was also placed in the instrument. Once the reagents and samples
were in their proper places, the ACL keypad was used to set the appropriate
specifications for the anti-Xa assay. An aliquot of 10 l of plasma was incubated for 1
minute at 37 ºC, followed by the addition of 100 l of bovine factor Xa. After five
minutes incubation at 37 ºC, 75 l of Spectrozyme FXa was added and the optical density
change at 405 nm was measured for 30 seconds.
The results were processed on an IBM compatible PC. The results were given as
optical density (O.D.) values which were converted to % factor Xa inhibition using the
following equation: % Inhibition = [100 - (O.D. sample/O.D.baseline) x 100]
Anti-factor IIa assay. The inhibition of factor IIa in human and primate plasma
samples was measured on the ACL Elite fast kinetics coagulation analyzer (BeckmanCoulter, Hialeah, FL), in the following manner. Test samples were prepared by placing
250 l of test plasma into individual test cups, which were then placed in an ACL test
cup carousel and their positions were recorded. Up to 40 plasma samples could be loaded
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into one carousel. Normal human or primate pool plasma and saline samples were
included in every carousel as controls. Human thrombin (Enzyme Research Laboratories,
South Bend, IN) was diluted to 5 U/ml in Xa/IIa buffer. The substrate, Spectrozyme TH
(Sekisui Diagnostics, Stamford, CT) was reconstituted by adding 5 ml of distilled water
(5 µM). The reagents were plated in their appropriate positions (thrombin in position 2
and Spectrozyme TH in position 3). A clean ACL rotor was also placed in the instrument.
Once the reagents and samples were in their proper places the ACL keypad was used to
set up the appropriate specifications for the anti-II assay. A 10 l aliquot of plasma was
incubated for 1 minute at 37 ºC, followed by the addition of 100 l of thrombin.
Following one-minute incubation at 37 ºC, 40 l of Spectrozyme TH was added, and the
optical density change at 405 nm was measured for 30 seconds.
The results were processed on an IBM compatible PC. The results were given as
optical density (O.D.) values which were converted to % factor IIa inhibition by using the
following equation: % Inhibition = [100 - (O.D. sample/O.D.baseline) x 100]
Chromogenic antiprotease assays (BioMed kits)
The USP potency was determined accordance to the specifications and directions
provided by the manufacturers (HYPHEN BioMed). Commercially available kits were
utilized. The anti-Xa and anti-IIa kits numbers were 221010 and 221025 respectively.
Heparin anti-Xa and anti- IIa assays are two-step chromogenic methods based on the
inhibition of a constant amount of factor Xa or factor IIa by the tested heparin in the
presence of exogenous AT (stage 1). Then any excess factor Xa or factor IIa hydrolyzes a
factor Xa specific chromogenic substrate or a factor IIa specific chromogenic substrate,
respectively (stage 2). There is an inverse relationship between the concentration of
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heparin and color development, measured at 405 nm using a SpectraMax® Plus384
Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA). Dilutions of the
drugs were prepared using AT-supplemented buffer at concentrations ranging from [0 –
10 µg/mL]. All results were plotted in terms of concentration effect curves.
AT supplemented system assay
A standard method used in the Hemostasis and Thrombosis Research Lab was
employed to determine the anti-Xa and anti-IIa activities in an AT supplemented system.
Here 250 µL of AT supplemented buffer containing varying concentrations of each of the
individual heparins in the range of 0-10 µg/mL was mixed with a known amount of
thrombin or factor Xa. The relative inhibition of these enzymes was measured using a
kinetic analyzer, monitoring the amidolysis of either Xa or IIa substrate. The IC50 was
calculated as the amount of heparin which produced 50% of the inhibition of the
enzymatic activity. The, anti-Xa and anti-IIa assays were performed on the ACL Elite
machine.
Heparinase-I digestion studies
Heparin pools were subjected to heparinase digestion in the following manner: An
aliquot of 70 µl of each agent (10 mg/ml) was added to an eppendorf tube along with 10
µl of CaCl2, 10 µl of either heparinase (10 U) or saline (vehicle control), and an
additional 10 µl of saline for a total volume of 100 µl. The solutions were mixed,
incubated for 30 minutes at 37°C, and then placed in a 100°C hot water bath for 3
minutes. The final heparinase concentration was 1.0 U. After digestion, the
heparinase/agent or saline/agent solutions were supplemented in normal human plasma to
obtain final concentrations ranging from 0 - 10 μg/ml. Anticoagulant activity was
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determined prior to and after the digestion using the APTT and thrombin time assays.
Antiprotease activity was determined prior to and after the digestion using anti-Xa and
anti-IIa assays. The molecular profile was determined prior to and after the digestion of
each pool using GPC in a high-performance liquid chromatography (HPLC) system.
Protamine sulfate neutralization studies
Heparin pools were supplemented in blood bank plasma to obtain final
concentrations ranging from 0 - 10 μg/ml. Protamine sulfate was added to the heparin
supplemented plasma to obtain a final protamine concentration of 10 μg/ml.
Anticoagulant activity was determined using the APTT and the thrombin time assays.
Antiprotease activity was determined using anti-Xa and anti-IIa assays.
Heparin induced thrombocytopenia (HIT) screening
The heparin derivatives were evaluated for their ability to promote platelet
aggregation induced by HIT antibodies according to the method of Brace (Brace et al.,
1990). Whole blood was drawn from healthy volunteers (n=10) using a double syringe
technique to avoid contamination by tissue factors released upon venipuncture (IRB #
9191051098). Standard venipuncture was performed using Vacutainer brand SafetyLokTM blood collection sets (23 G ¾, 0.6  19mm, Becton Dickinson and Company,
Franklin Lakes, NJ). Nine mls of blood was transferred to plastic test tubes containing 1
ml of 3.2% sodium citrate. Platelet rich plasma (PRP) was prepared by centrifuging the
citrated blood at 800 rpm (146 x g) for 15 minutes at room temperature. After removing
PRP, the remaining blood was spun further at 3,000 rpm (2,053 x g) for 15 minutes to
obtain platelet poor plasma (PPP). PPP was used to blank the aggregometer (PAP-8)
(BioData Corporation, Horsham, PA). Aggregations were performed in the following
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manner. Aliquots of 290 µl of PRP and 160 µl of HIT serum were warmed in a cuvette
for 1 to 2 minutes at 37oC. 5, 10, or 20 µl of a 1 mg/ml solution of each heparin being
tested was then added. The platelet aggregation response was monitored for 30 minutes.
Heat inactivated pooled HIT apheresis fluid was used as a source of HIT antibodies and
was obtained from patients (3-5) clinically diagnosed with heparin-induced
thrombocytopenia. The functionality of these antibodies was verified by using platelets
aggregation assays in the presence of heparins and by performing the quantitation of
these antibodies using a commercial available assay (GTI - PF4 ENHANCED® Solid Phase
ELISA) for the detection of PF4 heparin-dependent antibodies (GTI Diagnostics,
Waukesha, WI).
In Vivo studies in non-human primates
Comparative pharmacodynamics investigation of various heparin pools.
Twelve male and female Rhesus monkeys (Macaca mulatta) weighing 4.0 – 16.0 kg were
used for pharmacodynamics studies. The animals were animal housed in individual cages
in accordance with the Guide for the Care and Use of Laboratory Animals and the
National Research Council. All research was conducted in compliance with the
guidelines set forth by the Institutional Animal Care and Use Committee (IACUC),
Loyola University Medical Center and the Principles of Laboratory Animal Care.
The three heparin pools used in this study were BMH, OMH, and PMH. Each
agent was dissolved in 0.9% physiologic saline prior to administration to groups of
primates (n=12). Squeeze cages were used to anesthetize the primates with an
intramuscular injection of ketamine (10 mg/kg) + xylazine (1-2 mg/kg) based on the most
recent charted weight. The primates were weighed regularly on- and off-study and a
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record of these weights is kept in the animal room. Following attainment of anesthesia,
primates were removed from their cages and carried to the procedure room where they
were freshly weighed to accurately determine the dose of the test agent. The skin over the
saphenous vein was shaved as necessary and then cleaned using betadine and alcohol. A
baseline blood sample was collected by venipuncture of the saphenous vein. Test agent
was administered at a dose of 0.5 mg/kg intravenously via the saphenous vein. Additional
blood samples were collected at 15, 30, 60 and 120 minutes post-drug administration.
After administration of the test agent and after collection of each of the subsequent blood
samples, primates were returned to their cages and monitored continuously until they had
awakened from anesthesia and were able to sit up on their own. 10-15 minutes prior to
each blood draw, the sedation state of the animal was assessed. Additional doses of
ketamine were given intramuscularly as needed.
All blood samples were drawn using a double syringe technique, employing a 21gauge butterfly needle. After an initial ~1 ml volume (discard blood) was collected, the
syringe was changed, and a 2.7 ml sample was drawn and placed into a tube containing
0.3 ml 3.2% sodium citrate. The discard blood from the baseline samples were placed in
an EDTA tube and used to measure the complete blood count (CBC) of the primate.
Results of the CBC were recorded in the primate health record and reported to CMF.
Citrated blood samples were centrifuged, and aliquots of plasma were stored for
analysis of circulating drug levels and tissue factor pathway inhibitor levels. Circulating
concentrations of the drugs were calculated based on calibration curves constructed by
supplementing NHP with BMH, OMH, and PMH over a concentration range of 0 - 10
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μg/ml. Area under the curve values were calculated for each parameter and compared to
determine whether the heparins derived from different sources were bioequivalent.
Comparative pharmacokinetics investigation of various heparin pools.
Concentration-response curves were made by supplementing various heparin pools in
pooled baseline primate plasma over a concentration range of 0 to 10 µg/ml. Plasma
concentrations of various heparin pools were plotted against corresponding sample times
using graphing software, GraphPad Prism® Version 7.0 for Windows (GraphPad
Software, San Diego, CA). Best-fit curves were made and the drug concentration in each
primate blood sample was determined by extrapolation using the measured percent
inhibition of factor Xa and thrombin. The extrapolated plasma concentrations were used
to calculate values for the pharmacokinetic parameters such as elimination half-life
(T1/2), area under the plasma concentration time curve (AUC), systemic clearance (Cl)
and volume of distribution (Vd). Pharmacokinetic (PK) parameters were calculated by
non-compartmental analysis using PKSolver® software.
Data Processing and Statistical Analysis
The experimental data obtained in this dissertation is presented as the mean ±
standard deviation (SD) or mean ± standard error of the mean (SEM) and is indicated as
such throughout this document. The results obtained from the biochemical experiments
were analyzed using a two-way analysis of variance (ANOVA) followed by a Bonferroni
multiple comparison test. This analysis was used to determine statistically significant
differences between the effects of various heparins. Potency comparisons (IC50) were
compared using a one-way ANOVA followed by a Tukey multiple comparison test.
Other data were analyzed using one of the following statistical tests as such: Students t-

41
test (unpaired), one-way ANOVA with a Tukey multiple comparison test, Pearson’s chisquare test and Fisher’s exact test. In all cases a p value < 0.05 was considered
statistically significant. Computed p values were presented for each analysis. Graphs with
data and error bars were drawn using Microsoft Excel (Microsoft ® Corporation,
Redmond, WA) or GraphPad Prism for Windows (GraphPad Software, San Diego, CA).

CHAPTER FOUR
RESULTS
Physicochemical characterization of various heparins
The structural, compositional, and molecular characteristics of heparin and its
derivatives play an important role in the determination of their biological properties.
Therefore, molecular weight distribution, heparinase-I digestion profile and nuclear
magnetic resonance (NMR) analyses were performed on all agents to characterize their
physicochemical properties. These results are described in the following sections 1 and 2.
Gel-permeation chromatography
Molecular weight profiles. The molecular weight profiles for bovine, ovine and
porcine heparins were determined by gel-permeation chromatography (GPC) in a highperformance liquid chromatography (HPLC) system. The molecular weight of each
sample was determined by a narrow range calibration (NRC) method as previously
described in the ‘Materials and Methods’ section. The elution profiles for bovine, ovine
and porcine heparin pools which were analyzed using the NRC method, are shown in
Figure 4.
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B.

UV Profile

RI Profile

Figure 4. Elution profiles of bovine (black), ovine (blue) and porcine (green) pools as
measured by gel permeation chromatography (GPC) using the NRC method. Both the
UV 205 nm (A) and RI (B) detector methods were used. Panel A, shows the UV profile
whereas the panel B, shows the RI profile.
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The elution profiles using the UV detection method are shown in panel A, while
Panel B shows the elution profiles using the RI detection method. The calculated
molecular weights were comparable between the UV and RI detectors.
The elution time for each sample is defined as the time between the start of
separation (the time at which the solute enters the column or the beginning of the peak)
and the time at which the sample fully elutes (end of the peak). OMH and BMH showed
the broadest peaks, with elution times of approximately 19 and 20 minutes respectively,
indicating higher degree of heterogeneity compared to the PMH. PMH had elution time
which spanned approximately 16 minutes, which relatively a narrow peak indicating that
it has a higher degree of homogeneity compared to the other agents. The trends were
similar between the UV and RI profiles.
The molecular weight profiles for various batches of PMH, OMH and BMH
obtained with the UV and RI detectors for the NRC method are tabulated in Table 1, 2 &
3. Since heparins are heterogeneous in nature, the molecular weights of the various
heparins determined by GPC represent average molecular weights cross referenced to the
NRC curves.
As seen in Table 4, BMH pool exhibited the highest mean of weight average
molecular weight (Mw) of 21974 (±387) Da as measured by UV detection when using
the NRC method. The PMH and OMH exhibited slightly lower means of weight average
molecular weight (Mw) of 18601 (±534) Da and 18187 (±265) Da, respectively. The
weight average molecular weight (Mw) of the various heparin batches exhibited the same
rank order as shown in Tables 1, 2 and 3. The values of weight average molecular weight
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(Mw) of all heparins obtained by RI detector were comparable to the UV detector ones
with the same the rank order.
As seen in Table 4, BMH pool had slightly higher polydispersity of 1.35 (±0.07) as
measured by UV detection compared to all other pools when determined by the NRC
method. PMH and OMH pools had comparable polydispersity of 1.26 (±0.08) and 1.21
(±0.08) respectively. The polydispersity values of all pools produced by RI detector were
comparable to those obtained by UV detector with the same rank order. Polydispersity is
a measure of the homogeneity of the fractions making up the heparin sample. For each of
the heparins, the polydispersity decreased as the molecular weight decreased. The overall
data of these studies showed that, bovine, ovine and porcine have comparable molecular
weight profiles.
Heparinase-I Degradation. The effects of heparinase-I digestion on the
physicochemical properties of various heparin pools were subjected to heparinase-I
digestion. Previous studies have shown (Xiao et al., 2011), that heparinase 1 cleaves
heparins at both the GlcNS6S (1 → 4) IdoA2S and GlcNS3S6S (1 → 4) IdoA2S linkages
(see ‘List of Abbreviations’ for full description). Interestingly, Xiao et al (2011)
demonstrated that heparinase I had selectivity for the GlcNS3S6S (1 → 4) IdoA2S
linkages, which were found primarily within the antithrombin binding sites, compared to
the major disaccharide repeating unit GlcNS6S (1 → 4) IdoA2S.
In this study, heparinase digestion resulted in the fragmentation of each agent into
its oligosaccharide components; mainly, di, tetra, hexa, octa, and deca saccharides for all
the heparin pool samples.
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In Figures 5 & 6, Panel A shows the elution profiles for the non-digested samples,
while Panel B shows the elution profiles for the heparinase digested samples using the
UV detection and RI detection methods, respectively. As seen in Figures 5 & 6,
heparinase-I was clearly capable of depolymerizing the various heparin pools as evident
by the shift to the right of each peak and subsequent decrease in mean molecular weight
for all agents (B). Additionally, the similar post-digested mean molecular weights
(ranging from 2.9 to 3.2 kDa) for each heparin pool demonstrates a similar degree of
heparinase digestion.
The calculated molecular weights for pre and post heparinase digestion samples
were comparable with the UV and RI detectors. The results for the pre and post
heparinase digestion of BMH, OMH and PMH pools, obtained with the UV and RI
detectors for the NRC method, are tabulated in Table 5. All post heparinase digestion
pools showed comparable molecular weights as determined by UV and RI detections.
Heparinase digestion-index of OMH (80%), PMH (83%) and BMH (86%) heparins were
comparable when using UV detection. The same trend was noted when using RI
detection.
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Figure 5. Heparinase digestion of bovine (black), ovine (blue) and porcine (green) pools
as measured by GPC using the NRC method. Pre (A) and Post (B) heparinase elution
profiles were determined using the UV detection method. Heparinase (1 U/ml final
concentration) was incubated with various heparins (10 mg/ml, pH = 5.0) at 37°C for 30
min.
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A. Pre-heparinase digestion
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Figure 6. Heparinase digestion bovine (black), ovine (blue) and porcine (green) pools as
measured by GPC using the NRC method. Pre (A) and Post (B) heparinase elution
profiles were determined using the RI detection method. Heparinase-1 (1 U/ml final
concentration) was incubated with various heparins (10 mg/ml, pH = 5.0) at 37°C for 30
min.
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Nuclear Magnetic Resonance
BMH, OMH and PMH pools were investigated using one and bi dimensional
NMR methods. Proton and carbon assignments were made using 2D-NMR. Figures 7 and
8 showed the proton and carbon NMR spectra of heparin pools prepared from porcine,
bovine and ovine species. The spectral data were consistent with previously published
spectra of the same types of heparins (K. St. Ange et al.,2016) and (L. Fu, et al,.2013).
1H

Spectrum (Proton NMR). Figure 8 showed the proton NMR spectra (1H

Spectrum) of the various heparin pools. The Peak/ppm/assignment/residue were as
follow; A/5.51/H1/GlcNS6S; B/5.38/H1/GlcNS3S; C/5.34/GlcNY6X (where Y = Ac or
S and X = H or S); D/5.15/H1/IdoA2S; E/4.93/H1/ IdoA2S–GlcNS6S; E2/4.85/H1/
IdoA2S–GlcNS; F/4.67/H5/ IdoA2S; G/4.53/H1/GlcA; H/4.34/H6/GlcNS6X;
I/4.26/H2/IdoA2S; J/4.19/H6/GlcNS6S; K/4.13/H3/IdoA2S; L/4.03/H4/IdoA2S;
M/3.94/H5/GlcNS6S; N/3.78/H6/GlcNS; O/3.71/H4/GlcNS6S; P/3.58/H3/GlcA;
Q/3.32/H2/GlcA,GlcNS3SandGlc3 S; R/3.20/H2/GlcNS6X; S/1.95/CH3/GlcNAc.
The A-S assignments represent nineteen individual peaks in the porcine heparins in this
analysis. These peaks were used to reference the observed peaks to compare the BMH
and OMH preparations. For OMH, peak D was slightly higher and peak S was slightly
lower compared to PMH and BMH. In addition, no unidentified peak was observed in
OMH. However, for BMH, there were 2 peaks between peak C and peak D, one peak
next to peak F that were not present in PMH and OMH.
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13C

Spectrum (Carbon NMR). Figure 9 showed the carbon NMR spectra (13C

Spectrum). 13C hydrogen decoupled NMR experiments were performed on the samples
for 2000 scans. Peak/ppm/assignment/residue were noted as follow; A/101.97/C1/GalA;
B/99.39/C1/IdoA2S; C/96.70/C1/GlcNS and GlcNAc; D/66.37/C6/GlcNS2S;
E/61.10/C6/GlcNS2S–OH; F/57.91/C2/GlcNS; G/22.00/CH3/GlcNAc.
The A-G peaks represent seven components as detected by this method. They
were used as reference to compare BMH, OMH and PMH preparations. For the most
part, the 13C NMR spectra of the OMH and PMH were comparable. In contrast, the 13C
NMR spectrum of BMH was significantly different, especially in the region between 50
to 100 ppm.
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1H

NMR Spectra

Figure 7. Shows the proton NMR spectra (1H Spectrum) of pools prepared from porcine,
bovine and ovine heparins. 1H NMR experiments were performed on the samples for 32
scans with a five seconds relaxation delay.
13C

NMR Spectra

Figure 8. Shows the carbon NMR spectra (13C Spectrum) of pools prepared from
porcine, bovine and ovine heparins. 13C hydrogen decoupled NMR experiments were
performed on the samples for 2000 scans.
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In Vitro studies for functional profiling of heparins
The pharmacological actions of UFHs are predominately the result of their
interactions with a diversity of plasma proteins and the inhibition of serine protease
including factor Xa and thrombin. The ability of heparins to inhibit various serine
proteases is predominately mediated by the cofactors, AT and HCII. The binding of
heparins with AT and HCII is strongly influenced by the molecular weight (MW) and
structural composition of each heparin.
In this section, the effect of various heparins on anticoagulation and antiprotease
activity were determined using well-defined biochemical systems in which various
unfractionated heparins (UFHs) from different sources were supplemented in blood bank
plasma (BBP) at various concentrations, in order to determine the anticoagulant and
antiprotease properties of these agents.
Global anticoagulant assays
aPTT test. The anticoagulant effects of PMH, OMH and BMH as measured by
aPTT are shown in Figure 9. All agents were supplemented in BBP over a concentration
range of 0 to 10 µg/ml. OMH and PMH exhibited significant anticoagulant effects at
concentrations above 2.5 µg/ml compared to BMH. At concentrations above 5 µg/ml
BMH produced significantly longer clotting times compared to baseline values. While the
OMH and PMH provided comparable results, the BMH exhibited lower activities (Tables
6 & 7).
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A. aPTT test – various pools
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B. aPTT test – various batches
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Figure 9. Comparative anticoagulant effects in blood bank plasma (BBP) as measured by
the APTT assay. Heparin pools (A) and heparin means (B). All agents were
supplemented in the BBP over a concentration range of 0 to 10 µg/ml. Ovine and porcine
heparins exhibited significant (*p <0.05) anticoagulant effects at the 5 µg/ml
concentration compared to bovine ones. Additionally, ovine and porcine heparin pools
(A) produced longer clotting times compared to bovine heparin pool at all concentrations
except at 10 µg/ml.
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5U Ca2+ TT. Figure 10 shows the anticoagulant effects of various UFHs as
measured by the 5U Ca2+ TT assay after supplementation in BBP. As seen in panel A,
OMH and PMH pools exhibited significant anticoagulant effects at the 1.25 µg/ml
concentration, while BMH exhibited significant anticoagulant effects at 2.5 µg/ml
concentration compared to baseline values. The various heparin batches exhibited the
same trend as shown in panel B.
In the 5U Ca2+ TT assay, differences in the anticoagulant activities of the various
UFHs in BBP were noted (Tables 8 & 9). However, at concentrations above 1.25 µg/ml,
the anticoagulant effects of OMH and PMH were comparable. The overall anticoagulant
effects of the BMH in the 5U Ca2+ TT assay was lower compared to OMH and PMH at
concentrations lower than 1.25 µg/ml.
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A. TT test - various pools
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B. TT test - various batches
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Figure 10. Comparative anticoagulant effects in blood bank plasma (BBP) as measured
by the TT (5U Ca2+) assay. Heparin pools (A) and heparins mean (B). All agents were
supplemented in the BBP over a concentration range of 0 to 10 µg/ml. Ovine and porcine
heparins exhibited significant (p <0.05) anticoagulant effects at the 1.25 µg/ml
concentration, while bovine heparins exhibited significant (p <0.001) anticoagulant
effects at 2.5 µg/ml concentration.
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Chromogenic antiprotease assays
The inhibition of factor Xa and thrombin by various UFHs at a concentration
range from 0 to 10 µg/ml was studied. Antiprotease actions of these agents were
determined by amidolytic assays, which utilized substrates for factor Xa (Spectrozyme
Xa) and thrombin (Spectrozyme TH). Optical density changes were used to determine the
percent inhibition by each agent as compared to BBP.
Anti-Xa assays. As seen in Figure 11, PMH and OMH pools when supplemented
in BBP exhibited comparable anti-Xa activity at concentrations higher than 2.5 µg/ml
(Panel A). PMH and OMH inhibited factor Xa at the highest concentration (10 µg/ml) by
93.7 (±1.2) and 97 (±1.5) respectively. In contrast, BMH pool exhibited the lowest antiXa activity compared to other pools and inhibited factor Xa at its highest concentration
by 89.2 (±0.4). A similar trend was observed for the various heparin batches throughout
the concentration range from 0 to 10 µg/ml (Panel B). The percentage inhibition of factor
Xa for all heparin agents were noted at Tables 10 & 11.
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A. Anti-Xa - various pools
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B. Anti-Xa - various batches
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Figure 11. The inhibition of factor Xa in blood bank plasma (BBP) as measured by the
amidolytic anti-Xa assay. Heparin pools (A) and heparins mean (B). All agents were
supplemented in the BBP over a concentration range of 0 to 10 µg/ml. Porcine and ovine
heparins showed comparable activities and both were more potent inhibitors of factor Xa
than bovine heparins (p <0.01).
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Anti-IIa assays. Figure 12 shows the effect of various heparins on the inhibition
of thrombin after supplementation in BBP over a concentration range of 0 to 10 µg/ml.
PMH and OMH pools significantly inhibited thrombin to a greater extent than bovine
pool (Panel A).
As shown in Table 12, at the concentration of 10 µg/ml, PMH and OMH pools
inhibited factor IIa by 84.2% (±0.7) and 89% (±0.5) respectively. While the BMH
inhibited factor IIa by 76% (±1.3) at the same concentration. The same trend was noted
among the various heparin batches at the concentration of 10 µg/ml as shown in Table
13. The OMH and PMH batches exhibited comparable anti-IIa activities while, the BMH
batches showed lower anti-IIa activity.
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A. Anti-IIa - various pools
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B. Anti-IIa - various batches
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Figure 12. The inhibition of thrombin in blood bank plasma (BBP) as measured by
the amidolytic anti-IIa assay. Heparin pools (A) and heparins mean (B). All agents
were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. Porcine
and ovine heparins showed comparable activities and both were more potent
inhibitors of thrombin than bovine ones (p <0.03).
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Chromogenic antiprotease assays (BioMed kits) for USP potency
The USP potency was determined in accordance with the specifications and
directions provided by the manufacturers (HYPHEN BioMed). Dilutions of the drugs
were prepared in an antithrombin (AT)-supplemented buffer at concentrations
ranging from 0 – 10 µg/mL. The drugs were compared using anti-Xa and anti-IIa
assays. All results were plotted in terms of concentration effect curves. As shown in
Figures 13 & 14, PMH and OMH pools showed comparable anti-Xa and anti-IIa
potencies compared to the BMH pool. USP potency results of all heparin pools as
determined by the chromogenic anti-Xa and anti-IIa assays were noted in Tables 14
&15. The USP potency of PMH pool as measured by anti-Xa assay was 190 ±1.4
U/mg, whereas the OMH pool exhibited comparable potency of 197 ±2.8 U/mg. In
contrast, the USP potency of the BMH pool was much lower (135 ± 2.1 U/mg). The
USP potency as measured by anti-IIa assay showed the same trend. OMH and PMH
pools exhibited comparable potencies of 200 ±1.2 U/mg and 186 ± 1.4 U/mg
respectively. However, the BMH pool exhibited lower potency of 131 ± 1.3 U/mg
compared to others. The anti-Xa - IIa ratio for all heparins pools were comparable.
The various heparin batches showed the same trend in term of anti-Xa, Anti-IIa and
anti Xa-IIa ratio (Table 15).
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A. USP potency of various pools - anti-Xa assay

250

*

225

*

P o te n c y (U /m g )

200
175
150
125
100
75
50
25

P

l
o
o
P
e
in
O

B

o

o

v

v

rc

in

in

e

e

P

P

o

o

o

o

l

l

0

B. USP potency of various batches - anti-Xa assay
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Figure 13. Comparative USP potencies as measured by the chromogenic anti-Xa
assay (Hyphen Kits). Heparin pools (A) and heparins mean (B). The USP potency of
porcine and ovine heparins were comparable. In contrast, the USP potency of the
bovine heparins was significantly lower compared to others (*p <0.05).
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A. USP Potency of various pools – anti-IIa assay
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B. USP potency of various batches – Anti-IIa assay
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Figure 14. Comparative USP potencies as measured by the chromogenic anti-IIa assay
(Hyphen Kits). Heparin pools (A) and heparins mean (B). The USP potency of porcine
and ovine heparins were comparable. In contrast, the USP potency of the bovine heparins
was significantly lower compared to others (*p <0.05).
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AT supplemented system Assays
A standard method used in the Hemostasis and Thrombosis Research Lab was
employed to determine the anti-Xa and anti-IIa activities in an AT supplemented
system (see materials and methods). UFHs were supplemented in a purified AT
system over a concentration range of 0-10 µg/mL and were mixed with a known
amount of thrombin or factor Xa. The potency of each agent is presented in terms of
IC50 (Tables 16 &17). Briefly, concentration verses percent inhibition was plotted and
the linear portion of each curve was used to determine the IC50 value by extrapolating
the concentration required to produce 50% inhibition.
Figure 15 shows that PMH and OMH pools, when supplemented in AT system,
exhibited the highest anti-Xa potency with IC50 values of 2.72 (±0.04) µg/ml and
2.26 (±0.06) µg/ml, respectively, while BMH pool was significantly weaker to inhibit
factor Xa with IC50 value of 3.7 (±0.07) µg/ml (Panel A). Figure 16 also shows the
effect of the various pools on the inhibition of thrombin after supplementation in AT
system. Again, PMH and OMH pools showed the highest anti-IIa potency with IC50
values of 0.32 (±0.02) and 0.28 (±0.01) respectively, while the BMH pool was
significantly weaker to inhibit factor IIa with IC50 value of 0.50 (±0.01) (Panel A).
The same trend was noted with the various heparin batched as shown in Panel B. The
values of IC50 of heparin means were noted in Table 17.
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A. IC50 Values of anti-Xa and anti-IIa - various pools
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B. IC50 values of anti-Xa and anti-IIa - means of various batches
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Figure 15. Potency (IC50) comparison for various heparin agents when supplemented in
purified AT system as measured by the amidolytic anti-Xa and anti-IIa assays. Heparin
pools (A) and heparins mean (B). All agents were supplemented in the purified AT over a
concentration range of 0 to 10 µg/ml. Porcine and ovine heparins showed comparable
IC50 values and both were more potent inhibitors of factor Xa and thrombin than bovine
heparins (*p <0.03).
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Neutralization studies
UFH are widely used anticoagulants for interventional and surgical use. As such,
the ability to reverse the biological effects of heparins is very important. The
anticoagulant and bleeding effects of heparin are clinically neutralized by protamine
sulfate.
The objective of this study was to determine the neutralization profiles of various
heparin antagonists, such as heparinase-1 and protamine sulfate (PS). Protamine sulfate
was added to the heparin solutions to obtain a final antagonist concentration of 10 μg/ml.
whereas heparins were supplemented at 0 to 10 µg/ml range. For the heparinase-1
digestions study, agents were supplemented in BBP at a concentration range of 0 to 10
µg/ml. The heparin solutions were then supplemented with heparinase-1 to obtain a final
heparinase-1 concentration of 1U. The neutralization effects were measured using the
APTT, TT (5U Ca2+), anti-Xa and anti-IIa assays, which were previously discussed in the
‘Materials and Methods’ section. The data represent the mean ± standard deviation of two
independent experiments.
Protamine sulfate neutralization. Figure 16 shows the in vitro neutralization of
PMH, OMH and BMH pools by protamine as determined by the anticoagulant aPTT and
TT assays. In the APTT assay (Panel A), PS (10 μg/ml) was able to completely neutralize
the anticoagulant effects of the different concentrations of heparins at or below 5 μg/ml.
As shown in Panel B, again PS was able to completely neutralize the anticoagulant
effects of the different concentrations of heparins at or below 5 μg/ml. However, at 10
μg/ml, PS failed to neutralize the anticoagulants effects of all heparins.
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As shown in Figure 17, the same trend was observed for the amidolytic anti-Xa
and anti-IIa assays. PS was able to completely neutralize the different heparin pools at
concentrations below 5 μg/ml (Panels A & B). The results for the PS neutralization
profile of PMH, OMH and BMH pools, are tabulated in Tables 18, 19 & 20 respectively.
Heparinase-1 digestion. The neutralization of various heparin pools by
heparinase (HP) as measured by the APTT and TT assays are shown in Figure 18. When
determined by the APTT assay (Panel A), HP strongly neutralized the anticoagulant
effects of all heparin pools. The same trend was noted for TT assay (Panel B).
As shown in Figure 19, hepariase-1 (HP) was able to completely neutralize all
heparin pools at all concentration points as determined by the amidolytic anti-Xa and
anti-IIa assays (Panels A & B). These results indicate that, heparinase I cleaved
selectivity the GlcNS3S6S (1 → 4) IdoA2S linkages, which are present primarily within
the antithrombin binding sites. The results for the heparinase-1 neutralization profile of
PMH, OMH and BMH pools, are tabulated in Tables 21, 22 & 23 respectively.
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A. aPTT test
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Figure 16. Comparative neutralization profile of various heparin pools using protamine
sulfate as determined by the anticoagulant aPTT and TT assays. APTT assay (A) and TT
assay (B). All agents were supplemented in BBP over a concentration range of 0 to 10
µg/ml. Protamine sulfate was added to the heparin supplemented plasma to obtain a final
protamine concentration of 10 μg/ml. As seen in panels A and B, protamine sulfate
completely neutralized all heparin pools at concentrations at or below 5 μg/ml. aPTT,
activated partial thromboplastin time; TT, thrombin time.
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A. Anti-Xa assay
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B. Anti-IIa assay
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Figure 17. Comparative neutralization profile of various heparin pools using protamine
sulfate as determined by the amidolytic anti-Xa and anti-IIa assays. Anti-Xa (A) and antiIIa (B). All agents were supplemented in BBP over a concentration range of 0 to 10
µg/ml. Protamine sulfate was added to the heparin supplemented plasma to obtain a final
protamine concentration of 10 μg/ml. As seen in panel A and B, protamine sulfate
completely neutralized all heparin pools at concentrations at or below 5 μg/ml. Xa, factor
Xa: IIa, thrombin.
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A. aPPT test
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B. TT test
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Figure 18. Comparative neutralization profile of various heparin pools using heparinase1 as determined by the anticoagulant aPTT and TT assays. APTT assay (A) and TT assay
(B). Heparinase-1 (1 U/ml final concentration) was incubated with various heparin pools
(10 mg/ml, pH = 5.0) at 37°C for 30 min. As seen in panels A and B, heparinase-1
completely neutralized all heparin pools at all concentration points. aPTT, activated
partial thromboplastin time; TT, thrombin time.
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B. Anti-IIa assay
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Figure 19. Comparative neutralization profile of various heparin pools using
heparinase-1 as determined by the amidolytic anti-Xa and anti-IIa assays. Anti-Xa
(A) and anti-IIa (B). Heparinase-1 (1 U/ml final concentration) was incubated with
various heparin pools (10 mg/ml, pH = 5.0) at 37°C for 30 min. As seen in panels A
and B, heparinase-1 completely neutralized all heparin pools at all concentration
points. Xa, factor Xa; IIa, thrombin.
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Heparin induced thrombocytopenia (HIT) screening
Heparin induced thrombocytopenia (HIT) is a clinical event where antibody
mediated platelet aggregation occurs due to the presence of antibodies reactive against
the platelet factor 4 (PF4)/heparin complex. The reactive antibodies occur due to current
or previous exposure to heparin. Activation of platelets induces the release of
microparticles and ultimately leads to a reduction in the number of platelets, which is
termed thrombocytopenia. The purpose of this study was to examine the effects of
different heparin pools on HIT positive (+) antibody mediated aggregation of platelets
and how molecular weight and structural differences among these agents may contribute.
Platelet rich plasma (PRP) was incubated with the different heparin agents (final
concentrations of 10, 1 and 0.1 µg/ml) and serum from a known HIT positive pool.
Aggregation of platelets upon addition of the various heparin pools indicated a positive
HIT potential. Results from these studies are compiled in Table 24.
The effects of various heparin pools on HIT+ antibody mediated platelet
aggregation is depicted in Figure 20. In the control PRP, saline was only supplemented
with HIT + serum, 5 % (±1.2) aggregation was observed. All pools produced significant
platelet aggregation compared to control at concentrations of 10 and 1 µg/ml. However,
none of the pools showed a platelet aggregation response at 0.1 µg/ml. These results
suggest that all heparin pools have a similar HIT profile at the same concentrations.
Figure 21 depicts the effect of various heparin pools pre and post heparinase-1
digestion on HIT positive antibody platelet aggregation. All pre heparinase digestion
pools showed comparable platelet aggregation responses at concentrations of 10 and 1
µg/ml, however all pools showed no HIT response at 0.1 µg/ml. All post heparinase
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digestion pools showed no platelet aggregation responses at all concentrations. These
results suggest that, heparinase-1 completely neutralizes heparins from various animal
sources. Results from these studies are compiled in Table 25.
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Figure 20. The effect of various heparin pools on HIT antibody mediated platelet aggregation. All agents were tested at final
concentrations (FC) of 10 ,1 and 0.1 µg/ml. All agents produced significant platelet aggregation compared to saline (negative
control) at concentrations of 10 and 1 µg/ml, with no significant differences between each agent (Panels A &B). While at 0.1
µg/ml, all agents showed no platelet aggregation response (Panel C). AA was used as a positive control. AA, arachidonic acid;
FC, final concentration. The data represent the mean ± standard deviation (n=5 platelet donors).
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Figure 21. The effect of various heparin pools pre and post heparinase-1 digestion on HIT positive antibody platelet
aggregation. All agents were tested at final concentrations of 10 ,1 and 0.1 µg/ml. Post digested heparin pools exhibited no
platelet aggregation responses at all concentrations. AA was used as a positive control. AA; arachidonic acid, FC; final
concentration, PP; porcine pool, BP; bovine pool, OP; ovine pool. The data represent the mean ± standard deviation (n=5
platelet donors).
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In Vivo studies in non-human primates
Non-human primates can be used to study the pharmacodynamic and
pharmacokinetic properties of various heparins in an in vivo model similar to humans. To
elucidate how molecular weight and structure contribute to the pharmacodynamic and
pharmacokinetic properties, various heparin pools were given to primates intravenously
(IV) at doses previously described in the ‘Materials and Methods’ section. The
pharmacokinetic and pharmacodynamic profiles of PMH, OMH and BMH pools were
assessed using a variety of clotting and amidolytic assays (results shown in Appendix).
Concentration-response curves were made by supplementing various heparin
pools in pooled baseline primate plasma over a concentration range of 0 to 10 µg/ml.
Best-fit curves were made and the drug concentration in plasma samples collected at
various time points following heparin administration was determined by extrapolation
using the measured percent inhibition of factor Xa and thrombin.
The results are presented as the mean ± SD. Compiled data for the individual
experiments can be found in Tables 25 and 26 through in Appendix.
1. Comparative pharmacodynamic investigation of various heparin pools
In Figure 22, panel A depicts the aPTT response curves after 500 µg/kg IV
administration of various heparin pools to primates. OMH and PMH pools significantly
prolonged the clotting time compared to BMH pool at 15, 30, and 60 minutes. Maximal
effects for OMH pool (39.8 ± 2.3 sec) and PMH pool (38.8 ± 1.0 sec) were seen at 15
minutes post drug administration (PDA), while the BMH pool demonstrated maximal
anticoagulant effect (33.6 ± 2.9 sec) at 15 minutes PDA.
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In the aPTT assay where the PMH and OMH pools showed comparable
anticoagulant effects, BMH pool consistently showed lower effect at all time points. The
TT response curves are shown in panel B. OMH and PMH pools significantly prolonged
the clotting time at 60 minutes compared to the BMH pool. The plasma concentrationtime courses for each agent as determined by effects on aPTT and TT prolongation are
shown in Table 26.

77
A. aPTT test

50

P o r c in e P o o l

T im e (s e c o n d s )

45

*
*

B o v in e P o o l

40

O v in e P o o l

*
35

30

25

20
0

15

30

45

60

75

90

105

120

T im e ( m i n u t e s )

B. TT test
350

*

P o r c in e P o o l

300

T im e (s e c o n d s )

B o v in e P o o l
250

O v in e P o o l
200
150
100
50
0
0

15

30

45

60

75

90

105

120

T im e ( m i n u t e s )

Figure 22. The pharmacodynamic effects of 500 µg/kg IV porcine, bovine and ovine
pools administered to primates as measured by the anticoagulant aPTT and TT assays.
APTT assay (A) and TT assay (B). As seen in panel A, ovine and porcine pools
significantly prolonged the clotting time compared to the bovine pool (*p <0.05). Panel
B shows that ovine and porcine pools were significantly more effective than bovine pool
at prolonging the clotting time at 60 minutes (*p <0.03). The data represent the mean (±)
standard deviation (n=4).
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The time courses of the amidolytic anti-Xa activity of PMH, OMH and BMH
pools (500 µg/kg IV) are shown in Figure 23. In panel A, the anti-Xa activity expressed
as % inhibition at various time points is shown. At 30 and 60 minutes post-drug
administration, OMH and PMH pools led to significantly higher levels of factor Xa
inhibition compared to BMH pool. At 120 minutes post-drug administration, anti-Xa
activity of all agents were comparable. Peak anti-Xa activity for OMH and PMH pools
were (90.5 ±7.1 % Inh) and (88.5 ±5.5 % Inh) respectively. However, the peak anti-Xa
activity for the BMH pool was the lowest (79.3 ±6.3 % Inh).
Panel B shows the plasma concentration-time courses for each agent as
determined by their effects on anti-Xa activity. The peak plasma concentrations achieved
following administration of OMH pool (2.3 ± 0.1 U/ml) and PMH pool (2.2 ± 0.1 U/ml)
were significantly greater than after the administration of the BMH pool (1.5 ± 0.1 U/ml).
The time courses of the amidolytic anti-IIa activity of PMH, OMH and BMH
pools (500 µg/kg IV) are shown in Figure 24. In panel A, the anti-IIa activity expressed
as % inhibition at various time points is shown. At 15, 30, 60 and 120 minutes post-drug
administration, OMH and PMH pools produced a significantly higher level of thrombin
inhibition compared to the BMH pool. Peak anti-IIa activities for OMH and PMH pools
were (92.3 ±2.5 % Inh) and (89.5 ±3.4 % Inh) respectively. However, the peak anti-IIa
activity for the BMH pool was the lowest (80.5 ±2.6 % Inh).
Panel B shows the plasma concentration-time courses for each agent as
determined by their effects on anti-IIa activity. The peak plasma concentrations following
administration of OMH pool (2.2 ± 0.1 U/ml) and PMH pool (1.9 ± 0.3 U/ml) were
significantly greater (p < 0.001) than after BMH pool (1.2 ± 0.2 U/ml). The % inhibition
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results of anti-Xa and anti-IIa activities for all agents are shown in Table 26. The plasma
concentration-time courses for each agent as determined by the amidolytic anti-Xa and
anti-IIa activities are shown in Table 27.
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Figure 23. The pharmacodynamic effects of 500 µg/kg IV porcine, bovine and ovine
pools administered to primates as measured by the anti-Xa assay. As seen in panel A,
ovine and porcine pools significantly inhibited factor Xa activity at 30 and 60 minutes
compared to the bovine pool. Panel B shows the plasma concentration-time courses of
each agent as determined by effects on anti-Xa activity. At 15 and 30 minutes, the plasma
concentrations of ovine and porcine pools were significantly greater than the bovine pool
(*p <0.05). The data represent the mean (±) standard deviation (n=4).
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Figure 24. The pharmacodynamic effects of 500 µg/kg IV porcine, bovine and ovine
pools administered to primates as measured by the anti-IIa assay. As seen in panel A,
ovine and porcine pools significantly inhibited thrombin activity compared to the bovine
pool (*p <0.05). Panel B shows the plasma concentration-time courses of each agent as
determined by effects on thrombin activity. At 15, 30 and 60 minutes, the plasma
concentrations of ovine and porcine pools were significantly greater than the bovine pool
(*p <0.05). The data represent the mean (±) standard deviation (n=4).
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Comparative pharmacokinetic investigation of various heparin pools
The estimation of pharmacokinetic parameters calculated from plasma concentrationtime curves using the anti-Xa assay after IV administration of 500 µg/kg heparin pools to
non-human primates are shown in Figure 25. At the indicated dose, BMH pool (96 ± 13
mins) demonstrated a significantly longer half -life (t1/2) compared to PMH (60 ± 8 mins)
and OMH (40 ± 6 mins) pools (A). No differences in area under the curve (AUC) were
noted between each agent (B). Although BMH pool appeared to have a larger volume of
distribution (Vd), no significant differences were noted between each agent (C). No
differences in systemic clearance (Cl) were noted between each agent (D).
The estimation of pharmacokinetic parameters calculated from plasma concentrationtime curves using the anti-IIa assay after IV administration of 500 µg/kg heparin pools to
non-human primates are shown in Figure 26. At the indicated dose, BMH pool (105 ± 14
mins) demonstrated a significantly longer half -life (t1/2) compared to PMH (58 ± 8 mins)
and OMH (40 ± 3 mins) pools (A). No differences in area under the curve (AUC) were
noted between each agent (B). However, BMH pool (60 ± 8 ml/kg) exhibited a
significant larger volume of distribution (Vd) compared to PMH (38 ± 6 ml/kg) and
OMH (33 ± 6 ml/kg) pools (C). No differences in systemic clearance (Cl) were noted
between each agent (D). The results for the pharmacokinetic parameters of porcine,
bovine and ovine pools, are tabulated in Table 28.
In both anti-Xa and anti-IIa assays the relative concentration 15 mins after the
administration of OMH and PMH were higher than BMH. In anti-Xa assay, Cmax of OMH
(2.3 U/ml) and PMH (2.2 U/ml) heparins were significantly higher compared to the BMH
(1.5 U/ml). The same trend was noted in the anti-IIa assay, where the Cmax of OMH and
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PMH were 2.2 U/ml and 1.9 U/ml respectively. In contrast, the BMH showed lower Cmax
of 1.2 U/ml compared to the others.
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Anti-Xa assay

Figure 25. Estimation of pharmacokinetic parameters calculated from plasma
concentration-time curves using the anti-Xa assay after IV administration of 500 µg/kg
heparin pools to non-human primates. In panel A, bovine pool demonstrated a
significantly longer half -life compared to porcine and ovine pools (*p <0.05). No
significant differences in area under the curve, volume of distribution and clearance
between all pools as shown in panels B, C and D respectively. The data represent the
mean (±) standard deviation (n=4).
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Anti-IIa assay

Figure 26. Estimation of pharmacokinetic parameters calculated from plasma
concentration-time curves using the anti-IIa assay after IV administration of 500 µg/kg
heparin pools to non-human primates. In panel A, bovine pool demonstrated a
significantly longer half -life compared to porcine and ovine pools (*p <0.05). No
significant differences in area under the curve and clearance between all pools as shown
in panels B and D respectively. As shown in panel C, bovine pool exhibited a significant
larger volume of distribution (Vd) compared to porcine and ovine pools (*p <0.05). The
data represent the mean (±) standard deviation (n=4).

CHAPTER FIVE
DISCUSSION

Heparin, also known as unfractionated heparin (UFH), is a medication which
has been used as an anticoagulant and antithrombotic agent for over 80 years. It was
the first systemic anticoagulant used in the management of various thrombotic disorders
such as deep vein thrombosis, pulmonary embolism, and arterial thromboembolism.
Heparin is a heterogeneous drug in terms of its molecular weight (MW), structural
composition, and its biological actions. Preparations of heparin can contain fractions
that vary in molecular weight from 1.5 kDa to 30 kDa (Nader et al., 1974).
Most UFHs are derived from porcine intestinal mucosa, however, heparin has
also been manufactured from other mammalian sources such as bovine (cow) and ovine
(sheep) tissues. Nowadays, there are some concerns about a shortage of porcine heparin
as it is widely used in the manufacturing of the low molecular weight heparins
(LMWHs). Also, open-heart surgeries, hemodialysis and interventional cardiovascular
procedures are usually carried out utilizing unfractionated heparin. Moreover, due to
cultural and religious reasons in some countries, alternative sources of heparins are
needed. The FDA and other regulatory agencies are currently considering the
introduction of bovine unfractionated heparin for parenteral indications.
In this dissertation, the differences among bovine, ovine and porcine heparins were
investigated by comparing the biochemical and pharmacological effects of these
heparins in a variety of in vitro assays and in vivo animal models.
The initial studies consisted of molecular and compositional analyses which
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provided crucial data on the physicochemical characteristics of these agents. A
comprehensive biochemical analysis included extensive testing of the in vitro
anticoagulant and antiprotease actions in plasma-based systems. The purpose of these
studies was to determine the extent of biosimilarity between bovine, ovine, and porcine
heparins.
Physicochemical characterization of various heparins
Gel-permeation chromatography
Molecular weight profiles. As BMH, OMH and PMH are heterogeneous in
nature, their average molecular weights can be determined by using size exclusion
chromatography (SEC). SEC separates the components of the different heparins based
on MW, while offering the advantages of minimal sample preparation and a rapid
turnaround time (Ahsan et al., 1995). In this dissertation, in order to obtain MW data
from the HPLC elution profiles, calibration of the columns was performed using a set
of narrow range calibrators (NRC) consisting of thirteen fractions of heparin with
varying MWs ranging from 1.1 to 32 kDa. The MWs of these calibrators have been
previously reported (Ahsan et al., 1994).
Using the NRC method, with a few minor exceptions, the MWs determined by
the UV and RI detectors compared well. Therefore, the discussion on MW
determination will be based on data collected using the UV detector. The mean of
weight average molecular weight (Mw) of BMH (21.9 ±3.8 kDa) was slightly higher
compared to PMH (18.6 ±5.3 kDa) and OMH (18.2 ±2.6 kDa). The polydispersity,
which is a measure of heterogeneity, was slightly higher for BMH (1.35 ±0.07) than for
all other agents. In summary, these studies demonstrated a comparable molecular
weight profile of BMH, OMH and PMH. The other physiochemical parameters used to
characterize molecular weight profile of heparin were also comparable for all agents.
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Heparinase-I degradation. Heparinase-I cleaves heparins between the 2-sulfoiduronate and 2,6-disulfo- glucosamine residues (Nader et al., 1999; Xiao et al., 2011).
Overall, heparinase-I was clearly capable of depolymerizing the various heparins as
evident by the shift to the right of each peak and subsequent decrease in mean molecular
weight for all agents. Additionally, the similar post-digested mean molecular weights
(ranging from 2.9 to 3.2 kDa) for each heparin demonstrates a similar degree of
heparinase-I digestion. Moreover, the heparinase digestion indexes for all heparins
were comparable. Therefore, each of the three UFH’s were digested by heprinase-I in
a comparable fashion, suggesting a comparable amount of 2-sulfo-iduronate 2,6disulfoglucosamine linkages in the various heparins.
Nuclear magnetic resonance (NMR)
The 1H NMR spectra of PMH, OMH and BMH appeared largely comparable,
however some differences were noted (L. Fu et al., 2013; V. Ruiz et al., 2002).
Generally, in comparison to BMH, OMH is closer to PMH. PMH contained
considerably more N-acetylated glucosamine residues than either OMH or BMH as
seen by the relative intensity of the peak at δ 1.96 in the 1H NMR spectra (L. Fu et al.,
2013; M. Guerrini et al., 2001). In the anomeric region of the 1H NMR spectra, the
signals of 3-O-sulfo-N-acetylglucosamine and 3-O-sulfo-N-sulfoglucosamine
residues are useful for distinguishing among different species (L. Fu et al., 2013; V.
Ruiz et al., 2002; M. Guerrini et al., 2001). Additionally, the relative amounts of
iduronic acid and glucuronic acid residues are weakly dependent on the heparin
species (L. Fu et al., 2013; V. Ruiz et al., 2002). Moreover, differences in sulfation at
several specific positions (position 6 of glucosamine residues, position 3 of
glucosamine, and position 2 of the iduronic acid) were found between PMH and BMH
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(V. Ruiz et al., 2002; M. Guerrini et al., 2001). The peak D was slightly higher and
peak S was slightly lower for OMH and no unidentified peak is observed. However,
for BMH, there were 2 peaks between peak C and peak D, one peak next to peak F
that was not present in PMH and OMH. In addition, peaks intensity from peak I to
peak P were significantly different from PMH and OMH. Peak S intensity was also
higher than that in PMH and OMH. However, this univariate spectrum evaluation
does not provide enough information for the unambiguous characterization of
heparin’s species of origin. In a previous study, the correlation of NMR spectra of
heparin showed that PMH and OMH were similar in their profile (V. Ruiz et al.,
2002). In general, the 1H-NMR spectra of PMH and OMH were almost identical. Both
can pass USP specification for heparin, which have been published in the
pharmacopeia forum.
The 13C NMR spectra for PMH and OMH were almost identical. However, the
level of 6-O-sulfation of the glucosamine residues of OMH was higher. A lower
degree of acetylation was found in OMH in comparison to PMH and BMH. The 13CNMR spectrum of BMH was significantly different from that of PMH and OMH,
especially in the region between 50 to 100 ppm. Peak D and peak E represent
glucosamine 6-O-sulfation and glucosamine 6-OH, respectively. BMH had a lower
degree of 6-O sulfation compared to PMH and OMH as evidenced by the higher
intensity of peak E.
In Vitro studies
The therapeutic effects of heparins are predominately due to their interactions
with a diversity of plasma proteins including factor Xa and thrombin. The ability of
heparins to bind to and inhibit such serine proteases is predominately mediated by
cofactors such as AT and HCII.
The anticoagulant and antiprotease actions of BMH, OMH and PMH were
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studied following supplementation in blood bank plasma (BBP). The anticoagulant and
antiprotease effects were measured using the aPTT, thrombin time (TT), anti-Xa and
anti-IIa assays. The aPTT assay has already been discussed (Methods and Materials).
TT is a clot based assay which is designed to measure the conversion of fibrinogen to
fibrin following the addition of a known amount of thrombin into plasma (O' Shea et
al., 1971). This assay is primarily used to monitor antithrombin agents. In the current
studies, thrombin was supplemented with calcium chloride to lower the sensitivity of
the assay allowing for strong antithrombin drugs to produce a measurable effect. With
the addition of calcium, the baseline clotting time is reduced to approximately 12 -15
seconds from 20 seconds. Both the anti-Xa and Ila assays are chromogenic assays that
use factor Xa or IIa specific substrates onto which a chromophore has been linked.
Factor Xa or IIa cleaves the chromogenic substrate, releasing a colored compound that
can be detected with a spectrophotometer. The amount of color formed is directly
proportional to the amount of factor Xa or IIa present (Walenga and Hoppensteadt,
2004). These assays are a direct measurement of the effects of heparins on factors Xa
and thrombin only.
Global anticoagulant assays
In the aPTT assay, the anticoagulant effects of OMH and PMH heparins were
comparable and both exhibited significant anticoagulant effects at concentrations
above 2.5 µg/ml compared to BMH. At concentrations above 5 µg/ml BMH produced
significantly longer clotting times compared to baseline values. The concentrations of
heparin needed to double the aPTT for OMH (1.21 µg/ml) and PMH (1.25 µg/ml)
were lower compared to the BMH (1.9 µg/ml).
In the TT assay, OMH and PMH showed comparable anticoagulant effect and
both exhibited significant clotting time prolongation at the 1.25 µg/ml concentration,
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while BMH exhibited significant anticoagulant effects at a higher concentration (2.5
µg/ml).
Chromogenic antiprotease assays
The antiprotease activities of the heparins were measured in terms of the
inhibition of factor Xa and thrombin at a concentration range from 0 to 10 µg/ml.
PMH and OMH exhibited comparable anti-Xa activity at all concentrations. and both
of them inhibited factor Xa at the highest concentration (10 µg/ml) by 93.7% (±1.2%)
and 97% (±1.5%) respectively. In contrast, BMH exhibited a lower anti-Xa activity
compared to the other heparins, and its maximal inhibition of factor Xa (89.2%
±0.4%) was lower than that observed for PMH (93.7% ± 1.2%) and OMH (97% ±
1.5%).
The same pattern was noted with anti-IIa activity. At a concentration of 10
µg/ml, PMH and OMH inhibited thrombin by 84.2% (±0.7%) and 89% (±0.5%)
respectively. While BMH inhibited thrombin by 76% (±1.3%) at the same
concentration. The overall results from these global anticoagulants and amidolytic
antiprotease studies demonstrate that the BMH was consistently weaker than PMH and
OMH samples.
Chromogenic antiprotease assays (BioMed kits)
The USP potencies of the heparins were compared using chromogenic anti-Xa
and anti-IIa assays. Anti-Xa and anti-IIa assays are two-step chromogenic methods
based on the inhibition of a constant amount of factor Xa or factor IIa by the tested
heparin in presence of exogenous AT (stage 1). Any excess factor Xa or factor IIa
interacts with an enzyme specific chromogenic substrate (stage 2) to produce color,
which is inversely proportional to the heparin activity (FXa-CS # 11-65 and FIIa-CS #
01-38).
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The USP potency of PMH ranged from 189-190 U/mg, whereas the OMH
exhibited comparable potencies in the range of 191-197 U/mg. In contrast, the USP
potency of the BMH was much lower, ranging from 135-138 U/mg. The anti-Xa - IIa
ratios for all heparins were comparable. Overall results from these studies showed that
BMH has lower potency compared to OMH and PMH.
AT supplemented system assays
BMH, OMH and PMH heparins were supplemented in a purified AT system
over a concentration range of 0-10 µg/mL and were mixed with a known amount of
thrombin or factor Xa. The potency of each agent is presented in terms of its IC50. As
mentioned before, the IC50 value is the concentration required to produce 50%
inhibition.
The IC50 values for OMH and PMH were significantly lower than that of BMH,
as measured by both assays. These studies suggest that OMH and PMH are more
potent than BMH. A possible explanation of this observation could be that BMH has a
lower AT binding content compared to OMH and PMH which alters its ability to
inhibit factor Xa and thrombin. This observation has been reported in an earlier
publication (Naggi et al., 2015).
Neutralization studies
Heparin, and its analogues, are used during surgery and dialysis, and are often
used to coat indwelling catheters and other devices where the vascular system is
exposed. As such, the ability to reverse the biological effects of heparins is of
considerable importance. Presently, the anticoagulant and bleeding effects of heparin
are neutralized by protamine sulfate. The objective of these studies was to determine
the neutralization profiles of various heparin antagonists, such as protamine sulfate
(PS) and heparinase-I. The neutralizing effects of these antagonists were measured by
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comparing various clotting and antiprotease activities of heparins pre- and postneutralization.
Protamine sulfate neutralization (PS). Protamine sulfate (PS) is the main
heparin antagonist that has been used clinically for many years. The interaction of
protamine with heparin and its analogs have been extensively studied (Racanelli et al.,
1985).
In the anticoagulant aPTT and TT assays, PS was able to completely neutralize the
anticoagulant effects of the different heparins at concentrations below 5 μg/ml.
In antiprotease assays, PS was able to completely neutralize the different heparins
at concentrations below 5 μg/ml. However, at 10 μg/ml, the neutralization effects of
PS were variable. These results showed that heparins from different animal sources
have the same PS neutralization profiles. This is probably because OMH, BMH and
PMH have chain lengths containing greater than 18 saccharides which is essential for
optimal PS binding to heparin and its neutralizing effects (Harenberg et al., 1985;
Holst et al., 1994).
Heparinase-I digestion. Heparinase-I (HP) is an enzyme purified and
characterized from Flavobacterium heparinum (Lohse and Lindardt, 1992). The
cleavage of heparin by HP occurs at the linkage regions between the GlcNS6S (1→4)
IdoA2S and GlcNS3S6S (1→4) IdoA2S residues (Xiao et al., 2011). Xiao et al (2011)
demonstrated that the GlcNS3S6S (1→4) IdoA2S linkage, which is found mainly
within the AT binding site, is more susceptible to cleavage by heparinase-1 than the
major heparin disaccharide repeating unit GlcNS6S (1→ 4) IdoA2S.
These studies showed that the anticoagulant and antiprotease activities of all
heparins (BMH, OMH and PMH) were completely neutralized by heparinase-I to
almost the same degree. This is due to the exhaustive digestion of the chains present
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in these heparins.
Heparin induced thrombocytopenia (HIT) screening
One manifestation of heparin’s interactions with platelet factor 4 (PF4) is its
ability to cause heparin induced thrombocytopenia due to the presence of antibodies
reactive against the PF4/heparin complex (Chong et al., 1993). These reactive
antibodies occur due to current or previous exposure to heparin. Essentially, heparin
combines with endogenous PF4 to form an immune complex. This immune complex
then binds to the FcγRII receptors on circulating platelets and induces platelet
activation, promotes thrombin generation, and platelet aggregation. Activation of
platelets induces the release of microparticles and ultimately leads to a reduction in
the number of platelets, which is termed thrombocytopenia (Chong et al., 1993).
In these studies, the ability of various heparins to promote a HIT response was
examined in a platelet aggregation assay in which platelet rich plasma from normal
donors was mixed with heparins and serum collected from known HIT positive
patients. The aggregation response was used as an index for the potential to cause
HIT.
All test agents, BMH, OMH and PMH produced comparable levels of HIT+
antibody mediated aggregation at the same concentrations (10 and 1 µg /ml). None of
them showed Hit response at 0.1 µg /ml.
In Vivo studies in non-human primates
The main objective of this study was to evaluate the pharmacodynamics (PD)
and pharmacokinetic (PK) profiles of various heparins in non-human primates.
Bovine, ovine and porcine heparins were administered to primates intravenously (IV)
at a dose of 500 µg/kg. The PK and PD profiles of BMH, OMH and PMH were
determined using a variety of clotting and amidolytic assays (results shown in
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Appendix).
Concentration-response curves were made by supplementing BMH, OMH and
PMH in pooled baseline primate plasma over a concentration range of 0 to 10 µg/ml.
Best-fit curves were made and the drug concentration in each monkey blood sample
was determined by extrapolation using the measured percent inhibition of factor Xa
and thrombin. The pharmacokinetic profiles of these agents were determined by noncompartmental analysis using PKSolver® software.
Since heparins from various animal sources (i.e. pig, cow and sheep) have
slight variability in molecular compositions, some differences in pharmacokinetics
can be expected. This may be due to the binding to plasma proteins, in particular with
Antithrombin and HCII. Furthermore, the vascular interactions of different heparins
may also differ.
Before discussing the PD and PK of these drugs, a few experimental
limitations should be mentioned. Firstly, there is inter-animal variability (i.e. hepatic
function, age, sex, and weight). Secondly, the results may also have been influenced
by practical limitations on the number of blood samples that could be collected and by
the number of primates that could be included in each treatment group.
Individual heparins were injected intravenously, where they exerted rapid
effects on both factor Xa and thrombin. All three drugs significantly prolonged the
aPTT and TT clotting times with strong anticoagulant activity at 15 minutes postadministration. The peak plasma concentrations also correlated with this time point.
This peak anticoagulant activity was stronger for OMH and PMH than for BMH.
Administration of the various heparins at an IV dose of 0.5 mg/kg produced a
significant inhibition of factor Xa and thrombin at 15 minutes. This effect gradually
decreased until 120 minutes for all 3 agents. OMH and PMH had a significantly
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stronger anti-Xa and anti-IIa effects compared to BMH up to 60 minutes postadministration. However, all agents exhibited comparable anti-Xa and anti-IIa effects
at 120 minutes. The plasma concentration-time courses followed the activity in the
assay. Similar trends were observed in these assays. The only major difference was that
at 120 minutes, the anti-Xa effect of OMH was somewhat lower than PMH and BMH.
The pharmacokinetic parameters calculated from plasma concentration-time
curves using the anti-Xa assay after IV administration of 0.5 mg/kg heparins to nonhuman primates showed that, BMh exhibited a significantly longer half -life (t1/2)
compared to PMH and OMH. However, no differences in area under the curve (AUC)
were noted between each agent. Although BMH appeared to have a larger volume of
distribution (Vd), no significant differences were noted between each agent. And more
over, no differences in systemic clearance (Cl) were noted between each agent. The
pharmacokinetic parameters calculated from plasma concentration-time curves using
the anti-IIa assay showed the same trend except that BMH exhibited a significant larger
volume of distribution (Vd) compared to PMH and OMH.
Integrated discussion on the comparative structural and biological profiles of
heparins obtained from different origins
Ever since the discovery of heparins, mammalian tissues have been used to
isolate this anticoagulant. While the early discovery was in the dog liver (McLean et
al.,1959), subsequently beef and pig lung and mucosa have been used to prepare
heparins. The initial clinical batches of heparins were obtained from beef lung.
However, due to BSE virus and other cattle borne viral contaminants, its use was
stopped. This led to the widespread use of porcine mucosal heparins which are
currently clinically used. Sheep heparin obtained from mucosal tissue was also
developed and used in limited clinical indications. Because of the supply limitations

97
and quality issues with porcine heparin, the FDA has initiated plans to reintroduce
bovine heparin. Sheep heparins also provide a major source of heparin and it is
currently being developed (St. Ange et al., 2016).
The diversification of heparins is timely and will fill gaps in the use of
heparins brought about by cultural and religious reasons. The development of bovine
and ovine heparins will be widely accepted by countries with religious requirements.
Ovine heparin will be of major interest for the Indian subcontinent with highly
predominant Hindu and Muslim populations. Therefore, the availability of heparins
from bovine and ovine sources will make this anticoagulation acceptable to
individuals of all faiths. At the present time, a large amount of ovine mucosal tissue is
wasted, which otherwise can be used for pharmaceutical purposes. This will be
extremely valuable for managing supply and demand, and for providing alternate
sources during emergency situations such as the contaminants crisis in 2008 (Liu et
al., 2009).
The primary purpose of this thesis was to compare unfractionated BMH and
OMH with the commonly used PMH. In these comparative studies, updated
recommended profiling for the molecular and the structural attributes, biochemical
properties, pharmacological neutralization profile, and interaction with HIT antibodies
were investigated. In addition, the USP potencies of bovine and ovine heparins were
cross referenced to equate the potency in the gravimetric amounts. The
recommendations from regulatory agencies and USP were taken into considerations.
While the molecular weight profile of all the three heparins were comparable,
the biochemical properties and pharmacological profiling of the BMH exhibited some
differences from those of OMH and PMH. Notably, the BMH exhibited consistently
lower potency on a gravimetric basis, which was in the range of 30-40% lower than
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both the PMH and OMH. Thus, the results of this potency comparison suggest that to
obtained equivalent USP activity, higher amounts of BMH will be needed. It is
projected that potency adjusted BMH may exhibit comparable biochemical properties.
The difference in potency may partly be due to antithrombin binding region which
have been reported before (Casu et al., 1995).
In the current investigation, the BMH batches consistently showed lower USP
potency, ranging from 120-150 U/mg, in contrast to OMH and PMH which were
much higher. The primary reason for this lowered potency is most probably due to the
prevalence of the AT binding region in BMH which has been reported before (Naggi
et al., 2015). It is unlikely that inorganic ions such as sodium or chloride and the
water of hydration contribute to the lowered potency observed in BMH, as all the
heparin batches used in this study were stored in desiccated forms and were
lyophilized prior to storage. Thus, it is unlikely that water of hydration contributes to
the lowered potency observed with BMH. It should be stressed that the water of
hydration content may differ in heparins and is influenced by storage conditions. In
our studies, since the storage conditions were consistent for all heparins, it unlikely
that this factor contributes to the potency calculation.
The studies reported on the in vivo pharmacokinetics in primates where the
BMH, OMH and PMH were compared at a fixed gravimetric dosage of (0.5 mg/kg)
IV, confirmed the lowered potency of BMH in both the anticoagulant and antiprotease
assays. The proportionately decreased activities were a reflection of the composition
of mucosal heparin, and the results were consistent with the observed in vitro studies.
While some differences in the pharmacokinetic profiles were noted, the overall
behavior of the unfractionated heparins was comparable. Based on this, it is projected
that potency adjusted BMH at equivalent dosage may provide the same degree of
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anticoagulation as the OMH and PMH.
The USFDA and the US pharmacopoeia have initiated plans to reintroduce
bovine UFH for clinical use. At the same time, the Brazilian regulatory agency
ANVISA has recently released a BMH monograph which recognizes the lowered
potency of BMH and has included a potency limit of no less than 100 USP units per
milligram for acceptance criterion (Brazilian Heparin Monograph, 2017). Most of the
BMH preparations assayed using different methods provide widespread range assay
dependent potency values. In the current USP assay this potency ranged of 90-140
U/ml. The potency limit set forth by ANVISA is rather low and may compromise the
quality of this anticoagulant. The USP is currently working on the release of its own
monograph for bovine UFH and may likely follow the Brazilian monograph. It is also
unclear whether bovine heparin will be considered as a separate drug or whether it
will be considered as a biosimilar to PMH which will allow for interchangeability at a
potency adjusted level.
The minor differences noted in the microchemical structural between OMH
and PMH did not influence the in vitro and in vivo profiles of these two
anticoagulants, which were almost superimposable. Interestingly, the recent report in
which BMH was compared with PMH for the anticoagulation during cardiovascular
bypass surgery showed the comparability of these two agents in clinical settings
(Gomes WJ. et al., 2016).
It is noteworthy to state that, the current studies reported in this thesis showed
the biosimilarity and comparability of the unfractionated heparins obtained from the
sheep heparin in comparison to porcine heparins. Despite slightly lower molecular
weight and minor differences in degree of sulfation, the OMH was found to be
comparable to the PMH in both the in vitro and in vivo studies. The results obtained
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with both heparins were almost indistinguishable. It is projected that the ovine UFH
will be comparable to porcine heparin in the various indications where the porcine
heparin is used.

CHAPTER SIX
SUMMARY
This dissertation addresses the biochemical and pharmacological profiles of
various heparins derived from different animal sources. These studies explored
their interactions with the coagulation system and their
pharmacodynamic/pharmacokinetic behaviors. A summary of results from the
major experimental protocols included in this dissertation is provided below.
Physiochemical characterization
1. BMH, OMH and PMH heparins exhibited comparable molecular weight (MW)
profiles as determined by the size exclusion chromatography method. Each
heparin exhibited specific elution profiles. The MWs profile of each heparin, in
the range of 17.3 to 21.6 kDa, was cross referenced utilizing the narrow range
calibrators (NRC) method using UV detector.
2. These studies showed that BMH, OMH and PMH are degradable by heparinase-I
to similar degrees resulting in oligosaccharides of much lower molecular weights.
3. NMR analysis showed that the degree of sulfation of OMH was higher compared
to that found in PMH and BMH. However, OMH shows a lower degree of
acetylation compared to other heparins.
In vitro studies
1. The global anticoagulant and antiprotease effects of the BMH were consistently
lower than PMH and OMH samples. Ovine and porcine heparins exhibited
comparable anticoagulant and antiprotease activities.
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2. The chromogenic antiprotease assays using Biomed kits showed that the USP
potency of OMH and PMH were comparable and ranged from 180-210 U/mg. In
contrast, the USP potency of BMH was much lower and ranged from 110-150
U/mg. The anti-Xa / IIa ratio for all agents were comparable.
3. In the purified AT supplemented system, the OMH and PMH preparations
consistently showed lower IC50 values for both the thrombin and F-Xa inhibition
in contrast to the BMH.
4. Results from the neutralization studies showed that all heparins were consistently
neutralized by protamine sulfate and heparinase-I to similar degrees.
5. In the platelet based system studies, results demonstrated that there was no
difference between the HIT responses in the heparins from different species.
In Vivo studies in non-human primates
1. The anti-Xa and anti-IIa effects of OMH and PMH were significantly stronger
compared to BMH after IV administration. At equal gravimetric concentrations,
the overall anticoagulant and antiprotease effects of OMH and PMH were
comparable in the non-human primate model.
2. The pharmacokinetic parameters in all studies were calculated from the
concentrations derived from anti-Xa or anti-IIa activity using non-compartmental
analysis. Bovine heparins showed a longer half -life (t1/2) compared to porcine and
ovine heparins. No major variations in AUC, Vd and CL parameters.
Overall summary
Although, some structural and functional differences are noted between the
BMH, OMH and PMH, the results from this investigation clearly demonstrate the
comparability of OMH and PMH. The BMH consistently exhibited lowered
potency in all assays, which was also evident in the in vivo pharmacokinetic
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studies. Potency adjusted BMH may exhibit comparable anticoagulant effects to
OMH and PMH. Additional studies are warranted to validate this hypothesis.

CHAPTER SEVEN
CONCLUSIONS
Unfractionated heparin (UFH) is the first anticoagulant drug and has
successfully used clinically for over 80 years. Heparin, and its analogues, are used
during surgery, dialysis, and are often used to coat indwelling catheters and other
devices where the vascular system is exposed. Most of the heparins used clinically are
derived from porcine intestinal mucosa. However, heparins have also been
manufactured from mammalians such as cows and sheep. Recently there have been
attempts to generate bioengineered heparin. Currently there are some concerns about
the shortage of the porcine heparins as they are widely used in the manufacturing of
the low molecular weight heparins (LMWHs). Also, open-heart surgeries,
hemodialysis and intervention cardiovascular procedures are usually carried out with
anticoagulants and unfractionated heparins. Moreover, due to cultural and religious
reasons in some countries, alternative sources of heparins are needed. The FDA and
other regulatory agencies have considered re-sourcing of heparin for potential
substitution of porcine heparin and are currently reviewing this matter. Numerous
studies are ongoing to understand the structural-activity relationships of these various
heparins.
In this dissertation, heparins from different animal sources were studied to
determine the extent of biosimilarity between them. For these investigations, thirty
heparin batches were utilized. They included ten batches each BMH (21.6 kDa), OMH
(17.3 kDa), and PMH (18.9 kDa). Their activities in biochemical and biological assays
were compared to elucidate how their molecular
104
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composition and structural attributes contribute to their pharmacological actions.
These studies have shown that BMH, OMH and PMH exhibit comparable
molecular profiles. However, both 1H NMR and 13C NMR spectra have demonstrated
that PMH and OMH have similar structure and composition while BMH is
significantly different. These studies have also demonstrated that OMH and PMH
have comparable anticoagulant and antiproteases activities. However, BMH exhibited
somewhat lesser potencies compared to OMH and PMH in some of the functional
assays. Potency adjustment for in vivo usage may be required to obtain comparable
anticoagulant responses for the BMH. Neutralization studies have shown that all
heparins exhibit comparable profiles. The same trend was noted in the HIT antibody
interactions among heparins from different species. The anti-Xa and anti-IIa effects of
OMH and PMH were significantly stronger compared to BMH after IV administration
to non-human primates. Also, the pharmacokinetic parameters of all heparins were
comparable. However, BMH showed significantly longer half-life (t1/2) compared to
other heparins.
Based on these studies, it is projected that potency adjusted BMH at
equivalent dosage may provide the same degree of anticoagulant and antiprotease
activities as OMH and PMH. Thus, while PMH and OMH may be interchangeable,
BMH may require potency adjustment and thus exhibit a comparable profile to ovine
and porcine heparins.

APPENDICES:
DATA TABLES & EXTRA GRAPHS
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TABLE 1
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR TEN VARIOUS BATCHES OF
PORCINE HEPARINS AS MEASURED BY THE NRC METHOD

A- Detector/Method: UV (205 nm)/NRC
Agent
Batch 1
Batch 2
Batch 3
Batch 4
Batch 5
Batch 6
Batch 7
Batch 8
Batch 9
Batch 10
Mean ± SD

Mn (Da)
15879
15508
15399
15810
14599
14542
14402
16351
16120
16432
15504 (±757)

Mw (Da)
19204
18918
19002
19252
18265
18061
18041
19572
19485
19310
18911 (±581)

Polydispersity
1.28
1.27
1.27
1.27
1.28
1.26
1.27
1.23
1.32
1.31
1.28 (±0.02)

B- Detector/Method: RI /NRC
Agent
Batch 1
Batch 2
Batch 3
Batch 4
Batch 5
Batch 6
Batch 7
Batch 8
Batch 9
Batch 10
Mean ± SD

Mn (Da)
16179
16263
16845
16992
15441
15287
15769
16868
17315
16578
16354 (±686)

Mw (Da)
19793
19696
20305
20453
19085
18913
19433
20592
20638
20279
19919 (±627)

Polydispersity
1.31
1.29
1.31
1.31
1.29
1.35
1.29
1.33
1.32
1.32
1.31 (±0.02)

The molecular weights of the porcine batches were determined by gel permeation
chromatography. Mw is the weight average molecular weight, and Mn is the number average
molecular weight. In Table A (UV), Mw ranged from 18 to 19.5 kDa. In Table B (RI), Mw
ranged from 18.9 to 20.6 kDa. The calculated MWs were comparable between the UV and RI
detectors NRC, narrow range calibrators; SD, standard deviation.
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TABLE 2
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR TEN VARIOUS BATCHES OF
BOVINE HEPARINS AS MEASURED BY THE NRC METHOD

A- Detector/Method: UV (205 nm)/NRC
Agent
Batch 1
Batch 2
Batch 3
Batch 4
Batch 5
Batch 6
Batch 7
Batch 8
Batch 9
Batch 10
Mean ± SD

Mn (Da)
15929
17387
17470
17642
15979
17604
17312
18961
15934
15811
17203 (±845)

Mw (Da)
20455
22024
22126
22348
20494
22115
22058
23242
20722
20753
21634 (±954)

Polydispersity
1.38
1.37
1.41
1.42
1.34
1.32
1.32
1.33
1.39
1.37
1.37 (±0.03)

B- Detector/Method: RI /NRC
Agent
Batch 1
Batch 2
Batch 3
Batch 4
Batch 5
Batch 6
Batch 7
Batch 8
Batch 9
Batch 10
Mean ± SD

Mn (Da)
15901
17446
17461
17130
16448
17281
17803
16590
15899
16718
17868 (±662)

Mw (Da)
20836
22593
22614
22486
21259
22432
22912
22104
21003
21783
22002 (±741)

Polydispersity
1.37
1.38
1.42
1.37
1.34
1.34
1.34
1.32
1.34
1.35
1.36 (±0.03)

The molecular weights of the bovine batches were determined by gel permeation
chromatography. Mw is the weight average molecular weight, and Mn is the number average
molecular weight. In Table A (UV), Mw ranged from 20.4 to 23.2 kDa. In Table B (RI), Mw
ranged from 20.8 to 22.9 kDa. The calculated MWs were comparable between the UV and RI
detectors. NRC, narrow range calibrators; SD, standard deviation.
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TABLE 3
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR TEN VARIOUS BATCHES OF
OVINE HEPARINS AS MEASURED BY THE NRC METHOD

A- Detector/Method: UV (205 nm)/NRC
Agent
Batch 1
Batch 2
Batch 3
Batch 4
Batch 5
Batch 6
Batch 7
Batch 8
Batch 9
Batch 10
Mean ± SD

Mn (Da)
12423
12451
12556
12500
14056
13931
12330
11768
11714
12661
12639 (±781)

Mw (Da)
17423
17533
17645
17699
18862
18450
16244
15601
16324
17324
17311 (±1004)

Polydispersity
1.21
1.22
1.23
1.22
1.25
1.24
1.25
1.20
1.21
1.18
1.22 (±0.02)

B- Detector/Method: RI /NRC
Agent
Batch 1
Batch 2
Batch 3
Batch 4
Batch 5
Batch 6
Batch 7
Batch 8
Batch 9
Batch 10
Mean ± SD

Mn (Da)
12865
12761
12447
13330
14438
14424
12025
11796
11961
12889
12894 (±941)

Mw (Da)
17649
17585
17399
18199
19385
19272
16125
15587
16085
17400
17469 (±1281)

Polydispersity
1.22
1.21
1.21
1.20
1.24
1.24
1.23
1.22
1.19
1.22
1.22 (±0.02)

The molecular weights of the ovine batches were determined by gel permeation chromatography.
Mw is the weight average molecular weight, and Mn is the number average molecular weight. In
Table A (UV), Mw ranged from 15.6 to 18.8 kDa. In Table B, Mw ranged from 15.6 to 19.4
kDa. The calculated MWs were comparable between the UV and RI detectors. NRC, narrow
range calibrators; SD, standard deviation.
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TABLE 4
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR VARIOUS HEPARIN POOLS
AS MEASURED BY THE NRC METHOD

A- Detector/Method: UV (205 nm)/NRC

Agent

Mn (Da)

Mw (Da)

Polydispersity

Porcine pool

15544 (±93)

18601 (±534)

1.26 (±0.08)

Bovine pool

17262 (+-366)

21974 (±387)

1.35 (±0.07)

Ovine pool

13387 (±279)

18187 (±265)

1.21 (±0.08)

B- Detector/Method: RI /NRC

Agent

Mn (Da)

Mw (Da)

Polydispersity

Porcine pool

16794 (±166)

19724 (±458)

1.33 (±0.07)

Bovine pool

18286 (+-262)

23226 (±313)

1.31 (±0.09)

Ovine pool

14297 (±199)

18803 (±155)

1.26 (±0.06)

All results represent the mean (±) standard deviation (n=2). The molecular weights of different
heparin pools were determined by gel permeation chromatography. Mw is the weight average
molecular weight, and Mn is the number average molecular weight. The calculated MWs were
comparable between the UV and RI detectors. NRC, narrow range calibrators.
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TABLE 5
COMPARATIVE MOLECULAR WEIGHT PROFILES FOR VARIOUS HEPARIN POOLS
PRE AND POST HEPARINASE DIGESTION AS MEASURED BY THE NRC METHOD

A- Detector/Method: UV (205 nm)/NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity

Pre-Porcine Pool

15159 (±218)

18247 (±208)

1.24 (±0.08)

Pre-Bovine Pool

16389 (±221)

21986 (±151)

1.31 (±0.09)

Pre-Ovine Pool

13430 (±248)

16654 (±234)

1.21 (±0.6)

Post-Porcine

3115 (±92)

3147 (±196)

1.03 (±0.07)

Post-Bovine Pool

3130 (±197)

3086 (±123)

1.05 (±0.5)

Post-Ovine Pool

2994 (±132)

3312 (±189)

1.03 (±0.6)

B- Detector/Method: RI /NRC
Agent

Mn (Da)

Mw (Da)

Polydispersity

Pre-Porcine Pool

16156 (±149)

19646 (±208)

1.32 (±0.05)

Pre-Bovine Pool
Pre-Ovine Pool
Post-Porcine
Post-Bovine Pool

17154 (±219)
15003 (±147)
3152 (±87)
3754 (±217)

22282 (±258)
18088 (±142)
3223 (±159)
3361 (±88)

1.23 (±0.07)
1.28 (±0.6)
1.09 (±0.03)
1.05 (±0.2)

Post-Ovine Pool

3209 (±140)

3427 (±197)

1.06 (±0.3)

All results represent the mean (±) standard deviation (n=2). The molecular weights of different
heparins pools pre and post heparinase digestion were determined by gel permeation
chromatography. Mw is the weight average molecular weight, and Mn is the number average
molecular weight. The calculated MWs were comparable between the UV and RI detectors.
NRC, narrow range calibrators.
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TABLE 6
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARIN POOLS IN
BLOOD BANK PLASMA (BBP) AS MEASURED BY APTT ASSAY

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Porcine Pool
Time (sec)
300 (±0.0)
300 (±0.0)
108 (±2)
60 (±2)
32.5 (±1)
28.6 (±0.6)

Bovine Pool
Time (sec)
300 (±0.0)
207 (±4)
78 (±1.2)
45.9 (±1.4)
29 (±0.75)
28.6 (±0.6)

Ovine Pool
Time (sec)
300 (±0.0)
300 (±0.0)
137.5 (±3.5)
65.2 (±2.7)
38.8 (±0.2)
28.6 (±0.6)

TABLE 7
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARIN BATCHES IN
BLOOD BANK PLASMA (BBP) AS MEASURED BY APTT ASSAY
Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Porcine Batches
Time (sec)
300 (±0.0)
300 (± 0)
74.2 (±11)
43 (±4.5)
32.5 (±2.4)
28.2 (±0.0)

Bovine Batches
Time (sec)
300 (±0.0)
189.9 (±17)
76.5 (±4.5)
45.8 (±2.6)
34.7 (±2.7)
29 (±0.0)

Ovine Batches
Time (sec)
300 (±0.0)
300 (± 0)
66 (±6.3)
43 (±4.7)
32.9 (±3.2)
27.6 (±0.0)

All results represent the mean (±) standard deviation (n=2-10). Comparative anticoagulant
effects in blood bank plasma (BBP) as measured by the APTT assay. Heparin pools (Table 6)
and heparin means (Table 7). All agents were supplemented in the BBP over a concentration
range of 0 to 10 µg/ml. Ovine and porcine heparins exhibited significant (*p <0.05)
anticoagulant effects at the 5 µg/ml concentration compared to bovine ones. Additionally, ovine
and porcine heparin pools (Table 6) produced longer clotting times compared to bovine heparin
pool at all concentrations.
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TABLE 8
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARIN POOLS IN
BLOOD BANK PLASMA (BBP) AS MEASURED BY TT ASSAY

Concentration
(µg/ml)

Porcine Pool
Time (sec)

Bovine Pool
Time (sec)

Ovine Pool
Time (sec)

10
5
2.5
1.25
0.625
0

300 (±0.0)
300 (±0.0)
300 (±0.0)
300 (±0.0)
18.6 (±0.9)
9.4 (±0.2)

300 (±0.0)
300 (±0.0)
300 (±0.0)
82 (±5)
13 (±1.1)
9.4 (±0.2)

300 (±0.0)
300 (±0.0)
300 (±0.0)
300 (±0.0)
17.7 (±1.2)
9.4 (±0.2)

TABLE 9
COMPARATIVE ANTICOAGULANT EFFECTS FOR VARIOUS HEPARIN BATCHES IN
BLOOD BANK PLASMA (BBP) AS MEASURED BY TT ASSAY

Concentration

Porcine Batches

Bovine Batches

Ovine Batches

(µg/ml)

Time (sec)

Time (sec)

Time (sec)

10

300 (±0.0)

300 (±0.0)

300 (±0.0)

5

300 (±0.0)

300 (±0.0)

300 (±0.0)

2.5

300 (±0.0)

300 (±0.0)

300 (±0.0)

1.25

300 (±0.0)

45.2 (±6.6)

300 (±0.0)

0.625

19.45 (±2.2)

18.9 (±1.5)

25.1 (±2.3)

0

14.5 (±0.0)

16.2 (±0.0)

12.3 (±0.0)

All results represent the mean (±) standard deviation (n=2-10). Comparative anticoagulant
effects in blood bank plasma (BBP) as measured by the TT (5U Ca2+) assay. Heparin pools
(Table 8) and heparin means (Table 9). All agents were supplemented in the BBP over a
concentration range of 0 to 10 µg/ml. Ovine and porcine heparins exhibited significant (p <0.05)
anticoagulant effects at the 1.25 µg/ml concentration, while bovine heparins exhibited significant
(p <0.001) anticoagulant effects at 2.5 µg/ml concentration.
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TABLE 10
THE INHIBITION OF FACTOR XA BY VARIOUS HEPARIN POOLS IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Porcine Pool
% Inhibition
93.7 (±1.2)
87 (±1)
64.5 (±1)
33 (±0.1)
19.3 (±0.4)
0 (±0.0)

Bovine Pool
% Inhibition
89.2 (±0.4)
72.3 (±2.6)
50.4 (±1)
30.8 (±0.9)
17 (±0.6)
0 (±0.0)

Ovine Pool
% Inhibition
97 (±1.5)
91 (±1.1)
71.2 (±0.3)
45.7 (±1.1)
20.4 (±0.8)
0 (±0.0)

TABLE 11
THE INHIBITION OF FACTOR XA BY VARIOUS HEPARIN BATCHES IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY

Concentration
(µg/ml)
10
5
2.5
1.25
0.625
0

Porcine Batches
% Inhibition
92.5 (±1.4)
83.1 (±2.7)
55.6 (±5.3)
29.7 (±3.3)
17.9 (±1.4)
0 (±0.0)

Bovine Batches
% Inhibition
84.1 (±1)
66.7 (±5.3)
48.9 (±4.6)
28.5 (±3.6)
13.9 (±2.2)
0 (±0.0)

Ovine Batches
% Inhibition
95.5 (±1)
88.4 (±3.4)
65.3 (±3.1)
33.5 (±2.2)
15.3 (±2.4)
0 (±0.0)

All results represent the mean (±) standard deviation (n=2-10). The inhibition of factor Xa in
blood bank plasma (BBP) as measured by the amidolytic anti-Xa assay. Heparin pools (Table
10) and heparin means (Table 11). All agents were supplemented in the BBP over a
concentration range of 0 to 10 µg/ml. Porcine and ovine heparins showed comparable activities
and both were more potent inhibitors of factor Xa than bovine heparins (p <0.01).
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TABLE 12
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS HEPARIN POOLS IN
BLOOD BANK PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA
ASSAY

Concentration
(µg/ml)

Porcine Pool
% Inhibition

Bovine Pool
% Inhibition

Ovine Pool
% Inhibition

10
5
2.5
1.25
0.625
0

84.2 (±0.7)
77.4 (±1.5)
68.4 (±0.1)
54.3 (±1.4)
47.5 (±0.7)
0 (±0.0)

76 (±1.3)
65.6 (±2.3)
58 (±1.0)
42.3 (±0.5)
32.2 (±0.7)
0 (±0.0)

89 (±0.5)
84 (±0.95)
73 (±0.5)
57.5 (±0.5)
48.7 (±0.8)
0 (±0.0)

TABLE 13
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS HEPARIN BATCHES IN
BLOOD BANK PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA
ASSAY

Concentration
(µg/ml)

Porcine Batches
% Inhibition

Bovine Batches
% Inhibition

Ovine Batches
% Inhibition

10
5
2.5
1.25
0.625
0

84.6 (±1.56)
80.8 (±4)
69.9 (±4.3)
54.7 (±3.2)
48.1 (±4.7)
0 (±0.0)

80.7 (±2.2)
76.2 (±3.4)
54.5 (±2.9)
39.7 (±3.5)
23.6 (±3.4)
0 (±0.0)

88.1 (±2.9)
81.1 (±3.3)
70 (±3.8)
57.5 (±3)
51.4 (±3.2)
0 (±0.0)

All results represent the mean (±) standard deviation (n=2-10). The inhibition of thrombin
(Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay. Heparin
pools (Table 12) and heparin means (Table 13). All agents were supplemented in the BBP over a
concentration range of 0 to 10 µg/ml. Porcine and ovine pools showed comparable activities and
both were more potent inhibitors of thrombin (Factor IIa) than bovine heparins (p <0.03).
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TABLE 14
COMPARATIVE USP POTECIES FOR VARIOUS HEPARIN POOLS AS MEASURED BY
THE CHROMOGENIC ANTI-XA AND ANTI-IIA ASSAYS USING HYPHEN BIOMED
KITS

Agents

Xa (U/mg)

IIa (U/mg)

Xa/IIa Ratio

Porcine Pool

190 (±1.4)

186 (±1.4)

1.02

Bovine Pool

135 (±2.1)

131 (±1.3)

1.03

Ovine Pool

197 (±2.8)

200 (±1.2)

0.99

TABLE 15
COMPARATIVE USP POTECIES FOR VARIOUS HEPARIN BATCHES AS MEASURED
BY THE CHROMOGENIC ANTI-XA AND ANTI-IIA ASSAYS USING HYPHEN BIOMED
KITS

Agents

Xa (U/mg)

IIa (U/mg)

Xa/IIa Ratio

Porcine Batches

189.7 (±4.2)

183.9 (±5.3)

1.03

Bovine Batches

137.8 (±8.4)

139.8 (±11.1)

0.99

Ovine Batches

191.6 (±6.4)

187.6 (±7.1)

1.01

All results represent the mean (±) standard deviation (n=2-10). Comparative USP potencies as
measured by the chromogenic anti-Xa and Anti-IIa assays (Hyphen Kits). Heparin pools (Table
14) and heparin means (Table 15). The USP potency of porcine and ovine heparins were
comparable and ranged from 184-192 U/mg. In contrast, the USP potency of the bovine heparins
was much lower and ranged from 138-140 U/mg. However, the anti-Xa / IIa ratio of all heparins
were comparable.
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TABLE 16
POTENCY COMARISON FOR VARIOUS HEPARIN POOLS WHEN SUPPLEMENTED IN
PURIFIED AT AS MEAUSERED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA
ASSAYS

Anti-Xa

Anti-IIa

IC50 (µg/ml)

IC50 (µg/ml)

Porcine Pools

2.72 (±0.04)

0.32 (±0.02)

Bovine Pools

3.70 (±0.07)

0.50 (±0.01)

Ovine Pools

2.26 (±0.06)

0.28 (±0.01)

Drug

TABLE 17
POTENCY COMARISON FOR VARIOUS HEPARIN BATCHES WHEN SUPPLEMENTED
IN PURIFIED AT AS MEAUSERED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA
ASSAYS

Anti-Xa

Anti-IIa

IC50 (µg/ml)

IC50 (µg/ml)

Porcine Batches

2.52 (±0.26)

0.29 (±0.02)

Bovine Batches

3.67 (±0.4)

0.39 (±0.07)

Ovine Batches

2.08 (±0.29)

0.25 (±0.02)

Drug

All results represent the mean IC50 values (±) standard deviation (n= 2-10). Xa, factor Xa; IIa
thrombin; AT, antithrombin.

118
TABLE 18
NEUTRALIZATION PROFILE OF PORCINE HEPARIN POOL USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE
ASSAYS

Porcine Pool + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300 (±0.0)

300 (±0.0)

94 (±1.0)

86 (±0.0)

5

271 (±2.8)

300 (±0.0)

83.3 (±0.5)

84.5 (±0.7)

2.5

166 (±4.2)

300 (±0.0)

63.9 (±0.6)

75 (±0.0)

1.25

79.9 (±1.4)

300 (±0.0)

35.5 (±1.7)

64.5 (±4.9)

0.62

45 (±1.7)

18.5 (±0.7)

14.1 (±0.8)

46.7 (±0.9)

0

33 (±0.0)

11.1 (±0.4)

0.0 (±0.0)

0.0 (±0.0)

Porcine Pool + Protamine Sulfate
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

176.5 (±6.2)

300 (±0.0)

48.1 (±2.3)

90.4 (±1.5)

5

36.5 (±0.4)

13.3 (±0.6)

0.9 (±0.3)

6.9 (±0.9)

2.5

36 (±0.4)

13 (±0.4)

1.8 (±0.1)

6.7 (±0.6)

1.25

38.1 (±0.2)

13.3 (±0.2)

2.4 (±0.1)

6.6 (±0.5)

0.62

34.9 (±0.6)

13 (±0.3)

2.4 (±0.5)

7.3 (±0.2)

0

34.2 (±0.0)

10 (±0.1)

0.0 (±0.0)

0.0 (±0.0)

All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial
thromboplastin time; TT, thrombin time.
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TABLE 19
NEUTRALIZATION PROFILE OF BOVINE HEPARIN POOL USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE
ASSAYS

Bovine Pool + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300 (±0.0)

300 (±0.0)

83.3 (±1.5)

79 (±1.4)

5

192.5 (±3.5)

300 (±0.0)

64 (±2.1)

73 (±1.4)

2.5

140 (±1.5)

300 (±0.0)

40.3 (±1.3)

66.5 (±2.1)

1.25

59.9 (±1.1)

20 (±1.4)

18.9 (±0.8)

52.9 (±1.6)

0.62

37 (±1.2)

15.7 (±0.7)

4.6 (±1.8)

36.5 (±0.7)

0

33 (±0.0)

11.1 (±0.4)

0.0 (±0.0)

0.0 (±0.0)

Bovine Pool + Protamine Sulfate
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

94 (±1.8)

300 (±0.0)

24.1 (±2.2)

60.7 (±0.2)

5

37 (±0.7)

13 (±0.3)

0.9 (±0.1)

4.3 (±0.8)

2.5

37.8 (±0.1)

12.6 (±0.4)

1 (±0.2)

5.4 (±0.7

1.25

37.3 (±0.6)

11.9 (±0.3)

0.9 (±0.1)

7.0 (±1.1)

0.62

34.1 (±1.2)

11.1 (±0.4)

0.8 (±0.1)

8.2 (±0.6)

0

34.2 (±0.0)

10 (±0.1)

0.0 (±0.0)

0.0 (±0.0)

All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial
thromboplastin time; TT, thrombin time.
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TABLE 20
NEUTRALIZATION PROFILE OF OVINE HEPARIN POOL USING PROTAMINE
SULFATE AS DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE
ASSAYS

Ovine Pool + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300 (±0.0)

300 (±0.0)

95.4 (±0.8)

89 (±1.4)

5

300 (±0.0)

300 (±0.0)

89.9 (±0.3)

87 (±1.4)

2.5

173 (±1.4)

300 (±0.0)

74.6 (±1.0)

77 (±1.3)

1.25

78.2 (±2.4)

300 (±0.0)

49.8 (±2.1)

70.5 (±2.1)

0.62

48.6 (±2.3)

18.7 (±1.6)

23.6 (±1.3)

44 (±7.1)

0

33 (±0.0)

11.1 (±0.4)

0.0 (±0.0)

0.0 (±0.0)

Ovine Pool + Protamine Sulfate
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10
5

300 (±0.0)
37.1 (±1.6)

300 (±0.0)
12.1 (±1.0)

74.9 (±1.3)
0.7 (±0.3)

90.6 (±0.6)
7.4 (±0.1)

2.5

35.2 (±0.4)

12.3 (±0.4)

0.5 (±0.1)

7.5 (±0.1)

1.25

35.3 (±0.4)

11.1 (±0.4)

1.0 (±0.4)

8.4 (±0.4)

0.62

36.1 (±0.6)

13.4 (±0.7)

1.3 (±0.1)

9.3 (±0.8)

0

34.2 (±0.0)

10 (±0.1)

0.0 (±0.0)

0.0 (±0.0)

All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial
thromboplastin time; TT, thrombin time.
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TABLE 21
NEUTRALIZATION PROFILE OF PORCINE HEPARIN POOL USING HEPARINASE-1 AS
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS

Porcine Pool + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300 (±0.0)

300 (±0.0)

92.1 (±0.3)

84.3 (±1.1)

5

283.5 (±7.8)

300 (±0.0)

82.7 (±0.4)

78.5 (±3.7)

2.5

103 (±2.8)

300 (±0.0)

63.7 (±1.9)

66.7 (±2.4)

1.25

54 (±2.6)

300 (±0.0)

39.8 (±2.1)

53.6 (±2.9)

0.62

38.1 (±1.3)

19.7 (±0.9)

21.2 (±1.1)

44.9 (±2.7)

0

32.1 (±0.5)

13.7 (±0.6)

0.0 (±0.0)

0.0 (±0.0)

Porcine Pool + Heparinase-1
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

37 (±1.4)

15 (±1.8)

10.3 (±0.7)

15.9 (±0.8)

5

34.8 (±1.8)

18.2 (±1.0)

6.8 (±0.4)

13.8 (±0.6)

2.5

34.3 (±2.2)

15.8 (±0.6)

2.8 (±1.1)

7.4 (±0.6)

1.25

32.8 (±1.1)

15.9 (±1.5)

2.0 (±1.4)

4.4 (±0.9)

0.62

32.9 (±1.6)

14.1 (±1.7)

0.8 (±0.1)

3.0 (±0.6)

0

32.1 (±0.5)

13.7 (±0.6)

0.0 (±0.0)

0.0 (±0.0)

All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial
thromboplastin time; TT, thrombin time.
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TABLE 22
NEUTRALIZATION PROFILE OF BOVINE HEPARIN POOL USING HEPARINASE-1 AS
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS

Bovine Pool + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300 (±0.0)

300 (±0.0)

84.9 (±0.3)

78.9 (±0.4)

5

177.5 (±4.9)

300 (±0.0)

66.1 (±1.8)

67.2 (±2.6)

2.5

75.5 (±0.8)

300 (±0.0)

45.5 (±4.7)

57.2 (±1.2)

1.25

47.3 (±2.5)

18.1 (±0.6)

23.8 (±2.1)

41.9 (±1.6)

0.62

37.1 (±1.3)

14.6 (±2.3)

12.6 (±1.2)

33.5 (±0.8)

0

32.1 (±0.5)

13.7 (±0.6)

0.0 (±0.0)

0.0 (±0.0)

Bovine Pool + Heparinase-1
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

39.5 (±0.1)

17.9 (±1.1)

11.3 (±0.6)

15.3 (±0.5)

5

35.8 (±1.5)

15.7 (±1.0)

7.9 (±0.1)

12.9 (±1.1)

2.5

34.9 (±3.0)

15.4 (±0.5)

4.4 (±0.3)

8.9 (±1.2)

1.25

33.9 (±1.6)

15.5 (±1.6)

2.4 (±0.2)

4.7 (±0.8)

0.62

34.2 (±3.5)

15.6 (±2.4)

0.7 (±0.1)

3.1 (±0.6)

0

32.1 (±0.5)

13.7 (±0.6)

0.0 (±0.0)

0.0 (±0.0)

All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial
thromboplastin time; TT, thrombin time.
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TABLE 23
NEUTRALIZATION PROFILE OF OVINE HEPARIN POOL USING HEPARINASE-1 AS
DETERMINED BY VARIOUS ANTICOAGULANT AND ANTIPROTEASE ASSAYS

Ovine Pool + Saline
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

300 (±0.0)

300 (±0.0)

94 (±0.7)

88.8 (±0.3)

5

300 (±0.0)

300 (±0.0)

86.9 (±0.9)

85.4 (±0.8)

2.5

125 (±1.4)

300 (±0.0)

68.2 (±1.1)

73.1 (±1.3)

1.25

62.5 (±3.5)

300 (±0.0)

43.0 (±1.3)

56.5 (±0.7)

0.62

41.1 (±1.3)

22.7 (±2.3)

23.7 (±1.2)

47.7 (±2.4)

0

32.1 (±0.5)

13.7 (±0.6)

0.0 (±0.0)

0.0 (±0.0)

Ovine Pool + Heparinase-1
Concentration

aPTT

TT

Anti-Xa

Anti-IIa

(µg/ml)

(Sec)

(Sec)

(% Inhibition)

(% Inhibition)

10

38.1 (±1.2)

14.9 (±2.3)

13.8 (±0.1)

13.6 (±1.9)

5
2.5

35.5 (±2.1)
33.6 (±1.3)

14.1 (±1.8)
14.5 (±3.1)

7.6 (±1.5)
3.8 (±0.1)

11.2 (±0.6)
9.5 (±0.6)

1.25

33.3 (±1.1)

15.1 (±3.6)

4.9 (±1.7)

5.3 (±1.1)

0.62

32.4 (±1.0)

16.3 (±0.3)

0.9 (±0.1)

4.0 (±1.1)

0

32.1 (±0.5)

13.7 (±0.6)

0.0 (±0.0)

0.0 (±0.0)

All results represent the mean values (±) standard deviation (n= 2). aPTT, activated partial
thromboplastin time; TT, thrombin time.
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TABLE 24
THE EFFECT OF VARIOUS HEPARIN POOLS ON HIT POSITIVE ANTIBODY MEDIATED PLATELET AGGREGATION

FC=10 µg/ml

FC=1 µg/ml

FC=0.1 µg/ml

Agent
% Aggregation

Slope

% Aggregation

Slope

% Aggregation

Slope

Saline

5 (±1.2)

1.2 (±0.4)

5 (±1.2)

1.2 (±0.4)

5 (±1.2)

1.2 (±0.4)

AA

81 (±5)

42.8 (±4.1)

81 (±5)

42.8 (±4.1)

81 (±5)

42.8 (±4.1)

Porcine pool

65.4 (±3)

16 (±2.9)

72.4 (±8.6)

14.8 (±6.9)

6.2 (±2.4)

1.2 (±0.4)

Bovine Pool

56.2 (±7)

12.4 (±2.4)

71.4 (±5.4)

13 (±6.7)

4.4 (±2.3)

1(±0.0)

Ovine Pool

67.2 (±10.2)

18.8 (±6.9)

74.6 (±7.4)

18.4 (±6.4)

5 (±2.3)

1(±0.0)

All results represent the mean (±) standard deviation (n=5). FC, final concentration; HIT, heparin induced thrombocytopenia.
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TABLE 25
THE EFFECT OF VARIOUS HEPARIN POOLS PRE AND POST HEPARINASE-1 DIGESTION ON HIT POSITIVE ANTIBODY
PLATELET AGGREGATION

Heparin Pools +Saline
Agent
Saline
AA
Porcine pool
Bovine Pool
Ovine Pool

FC=10 µg/ml
% Aggregation
Slope
3.2 (±1.8)
1.0 (±0.0)
77 (±5.8)
46.2 (±3.6)
76.6 (±7.9)
20.5 (±3.0)
71.1 (±5.2)
23.6 (±3.3)
60.6 (±9.1)
16.5 (±1.7)

FC=1 µg/ml
% Aggregation
Slope
3.2 (±1.8)
1.0 (±0.0)
77 (±5.8)
46.2 (±3.6)
59.8 (±11.7)
15.4 (±2.3)
72.4 (±6.6)
20.4 (±2.3)
64.8 (±4.9)
22.4 (±4.0)

FC=0.1 µg/ml
% Aggregation
Slope
3.2 (±1.8)
1.0 (±0.0)
77 (±5.8)
46.2 (±3.6)
3.3 (±0.8)
2 (±1.0)
3.6 (±0.8)
2.2(±0.8)
4.8 (±1.1)
1.8(±0.8)

Heparin Pools + Heparinase-1
Agent
Saline
AA
Porcine pool
Bovine Pool
Ovine Pool

FC=10 µg/ml
% Aggregation
Slope
3.2 (±1.8)
1.0 (±0.0)
77 (±5.8)
46.2 (±3.6)
4.8 (±1.5)
1.8 (±0.8)
6.8 (±1.3)
1.8 (±0.8)
5.4 (±2.4)
2.0 (±0.9)

FC=1 µg/ml
% Aggregation
Slope
3.2 (±1.8)
1.0 (±0.0)
77 (±5.8)
46.2 (±3.6)
4 (±1.0)
2 (±1.0)
4.2 (±2.2)
2 (±1.0)
4.8 (±2.2)
2.6 (±1.1)

FC=0.1 µg/ml
% Aggregation
Slope
3.2 (±1.8)
1.0 (±0.0)
77 (±5.8)
46.2 (±3.6)
4.2 (±1.1)
1.4 (±0.5)
2.4 (±0.5)
1.8(±0.8)
3.8 (±0.8)
1.4(±0.5)

All results represent the mean (±) standard deviation (n=5). FC, final concentration; HIT, heparin induced thrombocytopenia.
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TABLE 26
COMPARATIVE PHARMACODYNAMIC INVESTIGATION OF VARIOUS HEPARIN POOLS AS DETERMINED BY
VARIOUS ANTIPROTEASE AND ANTICOAGULANT ASSAYS AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES

Drug

Time

Anti-Xa

Anti-IIa

aPTT

TT

0.5 mg/kg IV

(Minutes)

(% Inhibition)

(% Inhibition)

(Seconds)

(Seconds)

0
15
30
60

0.0 (±0.0)
88.5 (±5.5)
85.5 (±6.5)
73.0 (±9.8)

0.0 (±0.0)
89.5 (±3.4)
77.0 (±3.9)
69.8 (±2.5)

24.7 (±1.8)
38.8 (±1.0)
35.2 (±3.7)
30.9 (±2.8)

21.6 (±1.6)
300 (±0.0)
300 (±0.0)
300 (±0.0)

120

4.7.0 (±7.2)

52.0 (±3.8)

25.7 (±1.8)

22.7 (±1.4)

0
15
30
60

0.0 (±0.0)
79.3 (±6.3)
64.8 (±8.8)
52.5 (±6.1)

0.0 (±0.0)
80.5 (±2.6)
68.5 (±5.8)
51.5 (±4.2)

24.8 (±1.0)
33.6 (±2.9)
31.5 (±0.9)
28.2 (±1.4)

18.1 (±3.1)
300 (±0.0)
300 (±0.0)
27.0 (±1.8)

120

42.5 (±4.4)

41.3 (±5.7)

26.2 (±1.4)

19.9 (±2.1)

0
15
30
60

0.0 (±0.0)
90.5 (±7.1)
87.3 (±7.2)
78.3 (±9.1)

0.0 (±0.0)
92.3 (±2.5)
81.0 (±2.9)
70.8 (±4.3)

24.4 (±1.6)
39.8 (±2.3)
36.4 (±1.5)
29.9 (±1.9)

19.7 (±2.1)
300 (±0.0)
300 (±0.0)
300 (±0.0)

120

49.8 (±7.6)

57.0 (±6.1)

25.8 (±2.2)

22.8 (±1.4)

Porcine Pool

Bovine Pool

Ovine Pool

All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin; aPTT, activated partial thromboplastin time;
TT, thrombin time.
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TABLE 27
COMPARATIVE PLASMA CONCENTRATION-TIME COURSES OF VARIOUS HEPARIN POOLS AS DETERMINED BY
VARIOUS ANTIPROTEASE ASSAYS AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES

Drug
0.5 mg/kg IV

Porcine Pool

Bovine Pool

Ovine Pool

Time
(Minutes)
0
15
30
60
120
0
15
30
60
120
0
15
30
60
120

Anti-Xa
Concentration (U/ml)
0.0 (±0.0)
2.2 (±0.1)
1.5 (±0.3)
1.2 (±0.3)
0.6 (±0.3)
0.0 (±0.0)
1.5 (±0.1)
1.0 (±0.2)
0.8 (±0.2)
0.6 (±0.2)
0.0 (±0.0)
2.3 (±0.1)
1.7 (±0.1)
1.0 (±0.2)
0.4 (±0.1)

All results represent the mean (±) standard deviation (n=4). Xa, factor Xa; IIa, thrombin.

Anti-IIa
Concentration (U/ml)
0.0 (±0.0)
1.9 (±0.3)
1.7 (±0.3)
1.3 (±0.3)
0.6 (±0.3)
0.0 (±0.0)
1.2 (±0.2)
0.8 (±0.1)
0.3 (±0.2)
0.2 (±0.1)
0.0 (±0.0)
2.2 (±0.1)
1.7 (±0.2)
1.0 (±0.2)
0.4 (±0.1)
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TABLE 28
ESTAMATION OF PHARMACOKINETIC PARAMETERS CALCULATED FROM PLASMA CONCENTRATION TIME
CURVES AT A DOSE OF 0.5 MG/KG IV IN NON-HUMAN PRIMATES

U/ml
Test

Drug

Half-life; mins

AUC; (U*mins)/ml

Vd; ml/kg

Cl; ml/kg/mins

Anti-Xa

Porcine pool

60 (±8)

210 (±11)

39 (±6)

0.5 (±0.1)

Bovine pool

96 (±13)

185 (±12)

48 (±5)

0.4 (±0.1)

Ovine pool

40 (±6)

171 (±7)

34 (±4)

0.6 (±0.1)

Porcine pool

58 (±8.4)

205 (±14)

38 (±6)

0.5 (±0.1)

Bovine pool

105 (±14)

163 (±12)

60 (±8)

0.4 (±0.1)

Ovine pool

40 (±3)

168 (±9)

34 (±6)

0.6 (±0.1)

IV 500 μg/kg

Anti-IIa
IV 500 μg/kg

All results represent the mean (±) standard deviation (n=4). AUC, area under the curve; Vd, volume of distribution; Cl, clearance; Xa,
factor Xa; IIa, thrombin.
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Table 29
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL PORCINE HEPARIN BATCHES IN BLOOD
BANK PLASMA (BBP) AS MEASURED BY APTT ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

10

300

300

300

300

300

300

300

300

300

300

5

300

300

300

300

300

300

300

300

300

300

2.5

70

68

59

74

65

59.7

61.2

57.7

75.7

71.6

1.25

51

46

46

49

36

38.5

39

38.8

43.7

42.3

0.625

32.8

36

33

41

30

31.1

30.6

30.5

32.3

31.9

0

28

28

28

28

28

28

28

28

28

28

Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the APTT assay. All porcine heparin batches
were supplemented in the BBP over a concentration range of 0 to 10 µg/ml.
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Table 30
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL BOVINE HEPARIN BATCHES IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY APTT ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

10

300

300

300

300

300

300

300

300

300

300

5

183

169

203

170

218

210

207

182

175

182

2.5

74.9

70.5

79.2

73.7

81.7

85.9

75.7

73.4

72.3

78

1.25

45.7

44.7

44.5

43.5

45.2

46.5

44.2

43.2

49

52

0.625

35.5

39

29.7

34

35.5

33.5

33

33.2

35

39

0

29

29

29

29

29

29

29

29

29

29

Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the APTT assay. All bovine heparin batches
were supplemented in the BBP over a concentration range of 0 to 10 µg/ml.
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Table 31
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL OVINE HEPARIN BATCHES IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY APTT ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

10

300

300

300

300

300

300

300

300

300

300

5

300

300

300

300

300

300

300

300

300

300

2.5

80.9

77.5

85.5

96.4

62.4

66.9

68.3

66.5

78.3

59.6

1.25

46.9

44.4

48.7

51.4

39.2

41.8

39.4

38.4

42.8

37.4

0.625

34.3

34.2

35.9

36.6

30.7

31.6

30.3

30.8

31.2

29.6

0

28.2

28.2

28.2

28.2

28.2

28.2

28.2

28.2

28.2

28.2

Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the APTT assay. All ovine heparin batches
were supplemented in the BBP over a concentration range of 0 to 10 µg/ml.
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Table 32
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL PORCINE HEPARIN BATCHES IN BLOOD
BANK PLASMA (BBP) AS MEASURED BY TT ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

10

300

300

300

300

300

300

300

300

300

300

5

300

300

300

300

300

300

300

300

300

300

2.5

300

300

300

300

300

300

300

300

300

300

1.25

300

300

300

300

300

300

300

300

300

300

0.625

23.7

21

24.3

24.6

27.8

27.3

22.4

26.8

25.8

28.4

0

12.3

12.3

12.3

12.3

12.3

12.3

12.3

12.3

12.3

12.3

Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the TT (5U Ca2+) assay. All porcine heparin
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml.
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Table 33
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL BOVINE HEPARIN BATCHES IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY TT ASSAY

Concentratio
n

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

10

300

300

300

300

300

300

300

300

300

300

5

300

300

300

300

300

300

300

300

300

300

2.5

300

300

300

300

300

300

300

300

300

300

1.25

36

48

41

38

57

42

53

49

49

39

0.625

16

18

18.4

18.4

17.5

19.6

19.4

20.5

21.6

19.8

0

15.2

15.2

15.2

15.2

15.2

15.2

15.2

15.2

15.2

15.2

Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the TT (5U Ca2+) assay. All bovine heparin
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml.
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Table 34
COMPARATIVE ANTICOAGULANT EFFECTS FOR INDEVIDUAL OVINE HEPARIN BATCHES IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY TT ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

Time
(sec)

10

300

300

300

300

300

300

300

300

300

300

5

300

300

300

300

300

300

300

300

300

300

2.5

300

300

300

300

300

300

300

300

300

300

1.25

300

300

300

300

300

300

300

300

300

300

0.625

20

17

22

17.9

19.6

23

19.6

21

17.5

16

0

14.5

14.5

14.5

14.5

14.5

14.5

14.5

14.5

14.5

14.5

Comparative anticoagulant effects in blood bank plasma (BBP) as measured by the TT (5U Ca2+) assay. All ovine heparin
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml.
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Table 35
THE INHIBITION OF FACTOR XA BY VARIOUS PORCINE HEPARIN BATCHES IN BLOOD BANK PLASMA (BBP)
AS MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

10

92

91

92

94

91

93

94

95

92

91

5

82

84

87

80

82

84

78

83

87

84

2.5

59

64

54

51

52

57

62

46

52

59

1.25

33

28

28

26

30

31

23

34

31

33

0.625

20

17

17

17

16

18

18

18

19

19

0

0

0

0

0

0

0

0

0

0

0

The inhibition of factor Xa in blood bank plasma (BBP) as measured by the amidolytic anti-Xa assay. All porcine heparin
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.
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Table 36
THE INHIBITION OF FACTOR XA BY VARIOUS BOVINE HEPARIN BATCHES IN BLOOD BANK PLASMA (BBP)
AS MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

10

84

85

84

84

83

84

85

85

85

83

5

66

66

62

58

74

64

65

66

69

77

2.5

46

48

38

52

53

46

51

53

49

54

1.25

22

23

31

27

30

30

27

33

31

32

0.625

11

12

15

14

14

15

10

19

15

15

0

0

0

0

0

0

0

0

0

0

0

The inhibition of factor Xa in blood bank plasma (BBP) as measured by the amidolytic anti-Xa assay. All bovine heparin
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.
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Table 37
THE INHIBITION OF FACTOR XA BY VARIOUS OVINE HEPARIN BATCHES IN BLOOD BANK PLASMA (BBP) AS
MEASURED BY THE AMIDOLYTIC ANTI-XA ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

10

95

96

96

95

95

95

95

94

97

97

5

88

93

92

91

89

83

88

82

90

89

2.5

68

67

66

68

70

62

59

67

64

62

1.25

36

35

32

34

37

31

32

35

33

31

0.625

19

20

14

16

15

15

12

11

16

16

0

0

0

0

0

0

0

0

0

0

0

The inhibition of factor Xa in blood bank plasma (BBP) as measured by the amidolytic anti-Xa assay. All ovine heparin
batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.
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TABLE 38
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS PORCINE HEPARIN BATCHES IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

10

84

83

84

86

88

86

85

83

83

84

5

83

83

82

80

85

84

79

80

70

82

2.5

76

71

66

70

77

64

67

66

68

74

1.25

58

53

58

56

50

56

54

54

49

59

0.625

53

51

52

47

41

49

39

46

49

54

0

0

0

0

0

0

0

0

0

0

0

The inhibition of thrombin (Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay. All porcine
heparin batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.
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TABLE 39
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS BOVINE HEPARIN BATCHES IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

10

80

81

81

82

79

81

77

84

79

84

5

78

77

77

79

72

77

70

81

72

79

2.5

57

59

57

51

58

51

51

51

56

54

1.25

37

33

42

37

41

36

42

42

44

43

0.625

26

26

20

20

20

25

22

31

24

21

0

0

0

0

0

0

0

0

0

0

0

The inhibition of thrombin (Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay. All bovine
heparin batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.
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TABLE 40
THE INHIBITION OF THROMBIN (FACTOR IIA) BY VARIOUS OVINE HEPARIN BATCHES IN BLOOD BANK
PLASMA (BBP) AS MEASURED BY THE AMIDOLYTIC ANTI-IIA ASSAY

Concentration

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

(µg/ml)

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

% Inh.

10

89

88

89

87

87

85

87

90

85

96

5

85

83

81

80

80

79

81

87

74

82

2.5

76

74

73

71

65

71

64

70

70

66

1.25

60

61

63

59

56

54

58

55

53

57

0.625

55

46

54

55

54

49

52

52

46

51

0

0

0

0

0

0

0

0

0

0

0

The inhibition of thrombin (Factor IIa) in blood bank plasma (BBP) as measured by the amidolytic anti-IIa assay. All ovine
heparin batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml. %Inh., % inhibition.
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TABLE 41
COMPARATIVE USP POTECIES FOR VARIOUS HEPARIN BATCHES AS MEASURED BY THE CHROMOGENIC
ANTI-XA AND ANTI-IIA ASSAYS USING HYPHEN BIOMED KITS

Anti-Xa assay
Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

Porcine Batches

181

188

189

185

192

190

192

195

193

192

Bovine Batches

118

142

141

146

142

146

136

127

137

143

Ovine Batches

193

186

184

200

186

194

196

185

190

202

Agents

Anti-IIa assay
Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

U/mg

Porcine Batches

186

180

174

182

191

191

183

180

182

190

Bovine Batches

114

139

152

140

140

158

138

136

137

144

Ovine Batches

189

179

185

196

195

200

182

183

184

183

Agents

Comparative USP potencies as measured by the chromogenic anti-Xa and Anti-IIa assays using Hyphen BioMed kits.
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TABLE 42
POTENCY COMARISON FOR VARIOUS HEPARIN BATCHES WHEN SUPPLEMENTED IN PURIFIED AT AS
MEAUSERED BY THE AMIDOLYTIC ANTI-XA AND ANTI-IIA ASSAYS

Anti-Xa (IC50 µg/ml)
Agents
Porcine Batches
Bovine Batches
Ovine Batches

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

IC50

IC50

IC50

IC50

IC50

IC50

IC50

IC50

IC50

IC50

2.85
4.15
2.15

2.35
4.18
2.19

2.41
4.1
1.98

2.71
3.2
2.4

1.98
3.1
2.38

2.33
3.8
1.89

2.53
3.4
2.14

2.79
3.9
1.39

2.64
3.5
2.16

2.59
3.4
2.1

Anti-IIa (IC50 µg/ml)
Agents
Porcine Batches
Bovine Batches
Ovine Batches

Batch 1

Batch 2

Batch 3

Batch 4

Batch 5

Batch 6

Batch 7

Batch 8

Batch 9

Batch 10

IC50

IC50

IC50

IC50

IC50

IC50

IC50

IC50

IC50

IC50

0.25
0.49
0.27

0.29
0.46
0.25

0.31
0.47
0.24

0.29
0.43
0.29

0.31
0.36
0.28

0.32
0.4
0.24

0.29
0.34
0.25

0.27
0.34
0.21

0.28
0.3
0.24

0.29
0.32
0.25

Comparative IC50 values of various heparin batches when supplemented in AT purified system as measured by the amidolytic
anti-Xa and anti-IIa assays. All heparin batches were supplemented in the BBP over a concentration range of 0 to 10 µg/ml.
Xa, factor Xa; IIa thrombin; AT, antithrombin.
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A. UV Detector
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Figure 27. Elution profiles of various porcine batches as measured by gel permeation
chromatography (GPC) using the NRC method. Both the UV 205 nm (A) and RI (B)
detector methods were used. Panel A, shows the UV profile whereas the panel B, shows
the RI profile.
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Figure 28. Elution profiles of various bovine batches as measured by gel permeation
chromatography (GPC) using the NRC method. Both the UV 205 nm (A) and RI (B)
detector methods were used. Panel A, shows the UV profile whereas the panel B, shows
the RI profile.
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Figure 29. Elution profiles of various ovine batches as measured by gel permeation
chromatography (GPC) using the NRC method. Both the UV 205 nm (A) and RI (B)
detector methods were used. Panel A, shows the UV profile whereas the panel B, shows
the RI profile.
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Figure 30. Calibration curves as measured by gel permeation chromatography (GPC)
using the 13 narrow range calibrators (NRC method). Both the UV 205 nm (A) and RI
(B) detector methods were used. Panel A, shows the UV calibration curve whereas the
panel B, shows the RI calibration curve.
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